1 2<!DOCTYPE HTML> 3<html lang="en"> 4<head> 5 <meta charset="UTF-8"/> 6 7 8 9 10 <!--Tableau Script should be loaded only on insights at argenx website --> 11 12 13 <!-- Japan Font Family Library --> 14 15 16 17 <title>Get Your Patients Started | VYVGART Hytrulo® & VYVGART®</title> 18 <meta name="description" content="Enroll gMG patients for VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) & VYVGART (efgartigimod alfa-fcab). Find program details and support tools."/> 19 20 21 22 23 24 25 26 27 <meta name="template" content="content-page"/> 28 29 30 <meta name="viewport" content="width=device-width, initial-scale=1"/> 31 32 33 34 35 36 37 38 <meta name="content-page-ref" content="7wGbLkKsDgux8by4r5N0bE_UEcOhjk52Vitye0lMoL7bsEdAjNwq1IaaMKDW8k_MwMzZQIGup0zt-d163aBMj01WRzkhvuHH-9D1siWbnyo"/>
39<script defer="defer" type="text/javascript" src="/.rum/@adobe/helix-rum-js@%5E2/dist/micro.js"></script>
39 40<link rel="canonical" href="https://vyvgarthcp.com/gmg/enroll-patients"/> 41 42 43 44 45 46 47 48 49 50 51 <meta property="og:title" content="Get Your Patients Started | VYVGART Hytrulo® & VYVGART®"/> 52 53 <meta name="social-share-title" content="Get Your Patients Started | VYVGART® Hytrulo & VYVGART®"/> 54 55 56 57 <meta property="og:url" content="https://www.vyvgarthcp.com/content/vyvgart/us/en/hcp/gmg/enroll-patients/."/> 58 59 60 61 62 <meta name="social-share-title" content="Get Your Patients Started | VYVGART® Hytrulo & VYVGART®"/> 63 64 65 66 67 68 69 <meta property="og:type" content="website"/> 70 71 <meta name="social-share-title" content="Get Your Patients Started | VYVGART® Hytrulo & VYVGART®"/> 72 73 74 75 76 77 78 <meta property="og:site_name" content="VYVGART"/> 79 80 <meta name="social-share-title" content="Get Your Patients Started | VYVGART® Hytrulo & VYVGART®"/> 81 82 83 84 85 86 <meta property="og:image" content="https://www.vyvgarthcp.com/content/vyvgart/us/en/hcp/gmg/enroll-patients.thumb.800.480.png?ck=1779913740419"/> 87 88 89 <meta name="social-share-title" content="Get Your Patients Started | VYVGART® Hytrulo & VYVGART®"/> 90 91 92 93 94 95 96 <meta property="og:description" content="Enroll gMG patients for VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) & VYVGART (efgartigimod alfa-fcab). Find program details and support tools."/> 97 98 <meta name="social-share-title" content="Get Your Patients Started | VYVGART® Hytrulo & VYVGART®"/> 99 100 101 102 103 104<meta name="format-detection" content="telephone=no"/> 105 106 107 108 109 110 111 112 113 114 115 116 117 118 <meta name="veevacode" content="34444"/> 119 120 121 122 123<link rel="stylesheet" href="/etc.clientlibs/argenx/clientlibs/clientlib-argenx-global.lc-e74b47439d06e7c659135265a8a91a61-lc.min.css" type="text/css"> 124<link rel="stylesheet" href="/etc.clientlibs/argenx/clientlibs/clientlib-base.lc-431ea75cf562396066b99ae0cf15ec8f-lc.min.css" type="text/css"> 125 126 127 128 129 130 131 132 133 134 135<!-- refer to tickets WCM-1541 and WCM-1046 for the below script --> 136 137<!-- Data Layer -->
138<script> 139 window.dataLayer = window.dataLayer || []; 140 141 window.dataLayer.push({ 142 event: "form_engagement", 143 formName: "", 144 formStep:"", 145 eventAction:"", 146 eventLabel:"", 147 Formfieldtype:"" 148 }); 149</script>
149 150 151 152 <!-- Google Tag Manager --> 153
153<script>
vendor: 336 bytes, lines 153-157
153(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': 154 new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], 155 j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 156 ' https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); 157 })(window,document,'script','dataLayer','
157GTM-KX977PG
vendor: 3 bytes, line 157
157');
157</script>
157 158 <!-- End Google Tag Manager --> 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173
173<script type="text/javascript" src="//assets.adobedtm.com/43e912dd1903/9b76541cf2b6/launch-8b5f11d2b4eb.min.js"></script>
173 174 175 176 177 178 179<link rel="stylesheet" href="/etc.clientlibs/argenx/clientlibs/clientlib-vyvgarthcp.lc-eeddc0a3f092beb256601e26c50eaede-lc.min.css" type="text/css"> 180 181 182 183 184 185 186 187 188 189 190 191</head> 192<body class="page basicpage" id="page-c979c2ad2d"> 193 194<!-- Google Tag Manager (noscript) -->
vendor: 82 bytes, lines 194-197
194 195 196 197 <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=
197GTM-KX977PG
vendor: 94 bytes, lines 197-200
197" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript> 198 199 200
201<!-- End Google Tag Manager (noscript) --> 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216<div class="root container responsivegrid vyvgart-outage--container"> 217 218 219 220 221 <div id="container-e51be58c2d" class="cmp-container"> 222 223 <div class="fragment-importer"> 224 225 <div class="xfpage page basicpage"> 226 227 228 229 <div id="container-2b685bed7c" class="cmp-container"> 230 231 232 233<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 "> 234 235 <div class="container responsivegrid vyvgarthcp-container--header-wrapper aem-GridColumn aem-GridColumn--default--12"> 236 237 238 239 240 <div id="container-a32e2d75bd" class="cmp-container"> 241 242 <div class="container responsivegrid vyv-utils--hide-desktop"> 243 244 245 <div id="container-f81bb93d69" class="cmp-container"> 246 247 248 249<div class="aem-Grid aem-Grid--12 aem-Grid--small--12 aem-Grid--default--12 aem-Grid--xsmall--12 "> 250 251 <div class="teaser-new-rte-v2 teaser vyv-teaser--dropdown -justify-center -border-right__navy aem-GridColumn--small--none aem-GridColumn--small--7 aem-GridColumn--offset--xsmall--0 aem-GridColumn--default--none aem-GridColumn--xsmall--none aem-GridColumn aem-GridColumn--offset--small--0 aem-GridColumn--xsmall--7 aem-GridColumn--default--8 aem-GridColumn--offset--default--0"> 252<div id="teaser-new-rte-v2-40a0684339" class="cmp-teaser"> 253 254 255 256 <div class="cmp-teaser__content"> 257 258 259 260 261 <div class="cmp-teaser__title"> 262 <a class="cmp-teaser__title-link" href="https://argenx.com/content/dam/argenx-corp/products/vyvgart-hytrulo-prescribing-information.pdf"><p>Prescribing Information</p> 263</a> 264 </div> 265 266 267 268 269 270 271 272 <div class="cmp-teaser__action-container"> 273 274 275 <a class="cmp-teaser__action-link " href="https://argenx.com/content/dam/argenx-corp/products/vyvgart-hytrulo-prescribing-information.pdf" target="_blank">VYVGART Hytrulo</a> 276 277 278 279 280 281 <a class="cmp-teaser__action-link " href="https://argenx.com/content/dam/argenx-corp/products/vyvgart-prescribing-information.pdf" target="_blank">VYVGART</a> 282 283 284 285 286 287 <a class="cmp-teaser__action-link " href="https://argenx.com/content/dam/argenx-corp/products/vyvgart-hytrulo-IFU.pdf" target="_blank">PFS Instructions for use</a> 288 289 290 </div> 291 292 </div> 293</div> 294 295 296 297</div> 298<div class="button vyv-button--contact-a-rep aem-GridColumn--small--none aem-GridColumn--offset--xsmall--0 aem-GridColumn--default--none aem-GridColumn--xsmall--5 aem-GridColumn--xsmall--none aem-GridColumn aem-GridColumn--offset--small--0 aem-GridColumn--small--5 aem-GridColumn--offset--default--0 aem-GridColumn--default--4"> 299<a id="button-ae4972ea72" class="cmp-button" href="#contact-a-rep" target="_self"> 300 301 302 303 <span class="cmp-button__text">Contact a rep</span> <!--Added context for the button text--> 304</a> 305</div> 306<div class="teaser-new-rte-v2 teaser vyv-teaser--dropdown -theme-navy aem-GridColumn--default--none aem-GridColumn aem-GridColumn--default--12 aem-GridColumn--offset--default--0"> 307<div id="teaser-new-rte-v2-2f29771761" class="cmp-teaser"> 308 309 310 311 <div class="cmp-teaser__content"> 312 313 314 315 316 <div class="cmp-teaser__title"> 317 <a class="cmp-teaser__title-link" href="#active"><p>SELECT INDICATION: gMG</p> 318</a> 319 </div> 320 321 322 323 324 325 326 327 <div class="cmp-teaser__action-container"> 328 329 330 <a class="cmp-teaser__action-link " href="#active" target="_self">gMG</a> 331 332 333 334 335 336 <a class="cmp-teaser__action-link " href="/vyvgarthytrulo-cidp" target="_self">CIDP (VYVGART Hytrulo only)</a> 337 338 339 </div> 340 341 </div> 342</div> 343 344 345 346</div> 347 348 349</div> 350 351 </div> 352 353 354</div> 355<div class="submenu-header"> 356 357 <div> 358 <header class="cmp-submenu-header cmp-submenu-header-regular"> 359 <div class="cmp-submenu-header--mobile"> 360 <div class="cmp-submenu-header--top-section-mobile"> 361 <div class="cmp-submenu-header--utility-mobile" role="navigation" aria-label="Utility"> 362 363 <a class="cmp-submenu-header--utility-item-mobile showInMobileMenu " href="#isi" target="_self">Important Safety Information</a> 364 365 366 <a class="cmp-submenu-header--utility-item-mobile " href="https://www.argenx.com/product/vyvgart-prescribing-information.pdf" target="_blank">Prescribing Information</a> 367 <div class="cmp-submenu-header--utility-item-mobile utility-subnavigation-mobile"> 368 369 370 371 372 373 374 375 </div> 376 377 <a class="cmp-submenu-header--utility-item-mobile showInMobileMenu " href="https://vyvgart.com/" target="_blank">Patient Site</a> 378 379 380 <a class="cmp-submenu-header--utility-item-mobile showInMobileMenu " href="/gmg/resources/sign-up" target="_self">Stay Connected</a> 381 382 383 <a class="cmp-submenu-header--utility-item-mobile showInMobileMenu search-icon" href="#search" target="_self">Search</a> 384 385 386 <a class="cmp-submenu-header--utility-item-mobile utility-contact-a-rep" href="#contact-a-rep" target="_self">Contact a rep</a> 387 388 389 390 </div> 391 </div> 392 <div class="cmp-submenu-header--header-area-mobile"> 393 <div class="cmp-submenu-header--logo-mobile"> 394 <a href="/" target="_self"> 395 <img src="/content/dam/vyvgart/hcp/logos/co-branded-simplified-logo.svg" alt="VYVGART logo"/> 396 397 </a> 398 </div> 399 400 401 <div class="cmp-submenu-header__highlight"> 402 <div class="cmp-submenu-header__highlight-heading"> 403 404 </div> 405 <div class="cmp-submenu-header__highlight-title"> 406 SELECT INDICATION: gMG 407 </div> 408 <div class="cmp-submenu-header__highlight-eyebrow"> 409 VYVGART® (efgartigimod alfa-fcab) for intravenous infusion and VYVGART Hytrulo® (efgartigimod alfa and hyaluronidase-qvfc) for subcutaneous injection are each indicated for the treatment of generalized myasthenia gravis in adult patients who are anti-AChR (acetylcholine receptor) antibody positive. 410 </div> 411 <div> 412 <div id="highlight-sub-menu" class="cmp-submenu-header__highlight-submenu"> 413 <div class="cmp-submenu-header__highlight-submenu-items"> 414 415 <a target="_self" href="#active ">
416 <span>gMG</span> 417 </a> 418 419 </div> 420 421 <div class="cmp-submenu-header__highlight-submenu-items"> 422 423 <a target="_self" href="/vyvgarthytrulo-cidp"> 424 <span>CIDP (VYVGART Hytrulo only)</span> 425 </a> 426 427 </div> 428 </div> 429</div> 430 </div> 431 432 <div class="cmp-submenu-header--hamburger-menu-area"> <span class="cmp-submenu-header--hamburger-menu"></span> 433 <span class="cmp-submenu-header--close-button" style="display: none"></span> <span class="cmp-submenu-header--mobile-before-click"> </span><span class="cmp-submenu-header--mobile-after-click" style="display: none"> 434 </span> 435 </div> 436 </div> 437 </div> 438 439 <div class="cmp-submenu-header--top-section"> 440 <div class="cmp-submenu-header--logo-area"> 441 <div class="cmp-submenu-header--logo"><a href="/" target="_self"> <img src="/content/dam/vyvgart/hcp/logos/co-branded-simplified-logo.svg" alt="VYVGART logo"/></a> </div> 442 </div> 443 444 445 <div class="cmp-submenu-header__highlight"> 446 <div class="cmp-submenu-header__highlight-heading"> 447 448 </div> 449 <div class="cmp-submenu-header__highlight-title"> 450 SELECT INDICATION: gMG 451 </div> 452 <div class="cmp-submenu-header__highlight-eyebrow"> 453 VYVGART® (efgartigimod alfa-fcab) for intravenous infusion and VYVGART Hytrulo® (efgartigimod alfa and hyaluronidase-qvfc) for subcutaneous injection are each indicated for the treatment of generalized myasthenia gravis in adult patients who are anti-AChR (acetylcholine receptor) antibody positive. 454 </div> 455 <div> 456 <div id="highlight-sub-menu" class="cmp-submenu-header__highlight-submenu"> 457 <div class="cmp-submenu-header__highlight-submenu-items"> 458 459 <a target="_self" href="#active "> 460 <span>gMG</span> 461 </a> 462 463 </div> 464 465 <div class="cmp-submenu-header__highlight-submenu-items"> 466 467 <a target="_self" href="/vyvgarthytrulo-cidp"> 468 <span>CIDP (VYVGART Hytrulo only)</span> 469 </a> 470 471 </div> 472 </div> 473</div> 474 </div> 475 476 477 <div class="cmp-submenu-header--utility"> 478 <div class="cmp-submenu-header--utility-wrapper" role="navigation" aria-label="Utility"> 479 480 481 <div class="cmp-submenu-header--utility-item "> 482 <a href="#isi" target="_self" class="showInMobileMenu ">Important Safety Information</a> 483 484 485 <span class="cmp-submenu-header--utility-divider"> | </span> 486 </div> 487 488 489 <div class="cmp-submenu-header--utility-item __with-sub"> 490 <a href="https://www.argenx.com/product/vyvgart-prescribing-information.pdf" target="_blank" class=" ">Prescribing Information</a> 491 <div class="cmp-submenu-header--utility-item-chevron"></div> 492 <div class="cmp-submenu-header--sub--utility"> 493 494 <a href="https://www.argenx.com/product/vyvgart-hytrulo-prescribing-information.pdf" target="_blank" class="cmp-submenu-header--subItem ">VYVGART Hytrulo</a> 495 496 <a href="https://www.argenx.com/product/vyvgart-prescribing-information.pdf" target="_blank" class="cmp-submenu-header--subItem ">VYVGART</a> 497 498 <a href="https://argenx.com/content/dam/argenx-corp/products/vyvgart-hytrulo-IFU.pdf" target="_blank" class="cmp-submenu-header--subItem ">PFS Instructions for use</a> 499 500 </div> 501 <span class="cmp-submenu-header--utility-divider"> | </span> 502 </div> 503 504 505 <div class="cmp-submenu-header--utility-item "> 506 <a href="https://vyvgart.com/" target="_blank" class="showInMobileMenu ">Patient Site</a> 507 508
509 <span class="cmp-submenu-header--utility-divider"> | </span> 510 </div> 511 512 513 <div class="cmp-submenu-header--utility-item "> 514 <a href="/gmg/resources/sign-up" target="_self" class="showInMobileMenu ">Stay Connected</a> 515 516 517 <span class="cmp-submenu-header--utility-divider"> | </span> 518 </div> 519 520 521 <div class="cmp-submenu-header--utility-item "> 522 <a href="#search" target="_self" class="showInMobileMenu search-icon ">Search</a> 523 524 525 <span class="cmp-submenu-header--utility-divider"> | </span> 526 </div> 527 528 529 <div class="cmp-submenu-header--utility-item "> 530 <a href="#contact-a-rep" target="_self" class=" utility-contact-a-rep ">Contact a rep</a> 531 532 533 <span class="cmp-submenu-header--utility-divider"> | </span> 534 </div> 535 536 537 </div> 538 539 </div> 540 541 </div> 542 543 <div class="cmp-submenu-header--main"> 544 545 546 <ul role="navigation" aria-label="Main" class="cmp-submenu-header--main-list cmp-submenu-header--left"> 547 548 <li class="cmp-submenu-header--mainSectionItem "> 549 <a href="/gmg" target="_self"> 550 <img class="cmp-submenu-header--main_logo"/> 551 <span>Home</span> 552 </a> 553 <div class=" urlDestination cmp-submenu-header--chevron-expand-no-subItems"> 554 </div> 555 556 <div class="cmp-submenu-header--chevron-collapse-no-subItems" style="display:none"></div> 557 558 559 560 </li> 561 562 <li class="cmp-submenu-header--mainSectionItem "> 563 <a href="#" target="_self"> 564 <img class="cmp-submenu-header--main_logo"/> 565 <span>About</span> 566 </a> 567 <div class=" subnavigationMainNav cmp-submenu-header--chevron-expand"> 568 </div> 569 570 <div class="cmp-submenu-header--chevron-collapse" style="display:none"></div> 571 572 <div class="cmp-submenu-header--sub"> 573 574 <a href="/gmg/about/gmg" target="_self" class="cmp-submenu-header--subItem">About gMG</a> 575 576 <a href="/gmg/about/moa" target="_self" class="cmp-submenu-header--subItem">Mechanism of action</a> 577 578 <a href="/gmg/about/explore-patient-profiles" target="_self" class="cmp-submenu-header--subItem">Explore patient profiles</a> 579 580 </div> 581 582 </li> 583 584 <li class="cmp-submenu-header--mainSectionItem "> 585 <a href="/gmg/clinical-data" target="_self"> 586 <img class="cmp-submenu-header--main_logo"/> 587 <span>Efficacy</span> 588 </a> 589 <div class=" urlDestination cmp-submenu-header--chevron-expand-no-subItems"> 590 </div> 591 592 <div class="cmp-submenu-header--chevron-collapse-no-subItems" style="display:none"></div> 593 594 595 596 </li> 597 598 <li class="cmp-submenu-header--mainSectionItem "> 599 <a href="/gmg/safety" target="_self"> 600 <img class="cmp-submenu-header--main_logo"/>
601 <span>Safety</span> 602 </a> 603 <div class=" urlDestination cmp-submenu-header--chevron-expand-no-subItems"> 604 </div> 605 606 <div class="cmp-submenu-header--chevron-collapse-no-subItems" style="display:none"></div> 607 608 609 610 </li> 611 612 <li class="cmp-submenu-header--mainSectionItem "> 613 <a href="#" target="_self"> 614 <img class="cmp-submenu-header--main_logo"/> 615 <span>Dosing</span> 616 </a> 617 <div class=" subnavigationMainNav cmp-submenu-header--chevron-expand"> 618 </div> 619 620 <div class="cmp-submenu-header--chevron-collapse" style="display:none"></div> 621 622 <div class="cmp-submenu-header--sub"> 623 624 <a href="/gmg/dosing/overview" target="_self" class="cmp-submenu-header--subItem">Dosing overview</a> 625 626 <a href="/gmg/dosing/tools" target="_self" class="cmp-submenu-header--subItem">Administration options</a> 627 628 </div> 629 630 </li> 631 632 <li class="cmp-submenu-header--mainSectionItem "> 633 <a href="#" target="_self"> 634 <img class="cmp-submenu-header--main_logo"/> 635 <span>Access</span> 636 </a> 637 <div class=" subnavigationMainNav cmp-submenu-header--chevron-expand"> 638 </div> 639 640 <div class="cmp-submenu-header--chevron-collapse" style="display:none"></div> 641 642 <div class="cmp-submenu-header--sub"> 643 644 <a href="/gmg/access/access-information" target="_self" class="cmp-submenu-header--subItem">Access information</a> 645 646 <a href="/gmg/access/local-coverage-tool" target="_self" class="cmp-submenu-header--subItem">Find local coverage</a> 647 648 <a href="/gmg/access/patient-support-program" target="_self" class="cmp-submenu-header--subItem">Patient support program</a> 649 650 </div> 651 652 </li> 653 654 <li class="cmp-submenu-header--mainSectionItem "> 655 <a href="/gmg/resources" target="_self"> 656 <img class="cmp-submenu-header--main_logo"/> 657 <span>Resources</span> 658 </a> 659 <div class=" urlDestination cmp-submenu-header--chevron-expand-no-subItems"> 660 </div> 661 662 <div class="cmp-submenu-header--chevron-collapse-no-subItems" style="display:none"></div> 663 664 665 666 </li> 667 668 <li class="cmp-submenu-header--mainSectionItem "> 669 <a href="/gmg/enroll-patients" id="submenu-header--enroll-patients-amethyst" target="_self"> 670 <img class="cmp-submenu-header--main_logo"/> 671 <span>Enroll patients</span> 672 </a> 673 <div class=" urlDestination cmp-submenu-header--chevron-expand-no-subItems"> 674 </div> 675 676 <div class="cmp-submenu-header--chevron-collapse-no-subItems" style="display:none"></div> 677 678 679 680 </li> 681 682 683 </ul> 684 <div class="cmp-submenu-header--adaptive-share-wrapper-mobile"> 685 686 687 </div> 688 689 </div> 690 </header> 691</div> 692 693</div> 694 695 696 </div> 697 698</div> 699 700 701</div> 702 703 </div> 704 705 706</div> 707 708 709 710 711 712 713</div> 714<main class="container responsivegrid"> 715 716 717 718 719 <div id="container-71e9ec16d7" class="cmp-container"> 720 721 <div class="container responsivegrid vyvgarthcp-container--fullbleed vyv-theme--co-branded"> 722 723 724 725 726 <div id="enroll-patients-hero" class="cmp-container" style="background-image:url(\2f content\2f dam\2fvyvgart\2fhcp\2fgMG_Building_Blocks_Gradient.jpg);background-size:cover;background-repeat:no-repeat;"> 727 728 <div class="container responsivegrid vyvgarthcp-container--content-gutter"> 729 730 731 732 733 <div id="container-0d1b55202c" class="cmp-container"> 734 735 <div class="text vyvgarthcp-color--white vyv-spacing--bottom-sm-5 vyvgarthcp-text--font-weight-sm"> 736<div id="text-6d309825de" class="cmp-text"> 737 <h1 style=" text-align: center; 738">Enroll your adult patients of all gMG serotypes and get them started with <b>VYVGART Hytrulo</b> or <b>VYVGART<sup>1,2*</sup></b></h1> 739 740</div> 741 742 743 744</div> 745<div class="text vyvgarthcp-color--white vyv-spacing--bottom-sm-8"> 746<div id="text-32cda8ed41" class="cmp-text"> 747 <p style=" text-align: center; 748"><b>Two ways to enroll patients in My VYVGART<sup>®</sup> Path</b></p> 749 750</div> 751 752 753 754</div> 755<div class="container responsivegrid"> 756 757 758 <div id="container-bfc3d518c5" class="cmp-container"> 759 760 761 762<div class="aem-Grid aem-Grid--12 aem-Grid--small--12 aem-Grid--default--12 aem-Grid--xsmall--12 "> 763 764 <div class="teaser-new-rte-v2 teaser vyv-spacing--bottom-sm-6 vyvgarthcp-spacing--desktop-bottom--none vyvgarthcp-button--primary vyvgarthcp-button--rounded-r4 vyv-teaser-image-auto-resize vyv-teaser-image-center-x aem-GridColumn--small--none aem-GridColumn--offset--xsmall--0 aem-GridColumn--default--none aem-GridColumn--xsmall--12 aem-GridColumn--xsmall--none aem-GridColumn aem-GridColumn--small--12 aem-GridColumn--offset--small--0 aem-GridColumn--default--6 aem-GridColumn--offset--default--0"> 765<div id="teaser-new-rte-v2-42389e9787" class="cmp-teaser"> 766 767 <div class="cmp-teaser__image"> 768<div data-cmp-is="image" data-cmp-lazythreshold="0" data-cmp-src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_257896284/container/container/teaser_new_rte_v2.coreimg{.width}.svg/1779913738993/ep-online-icon.svg" data-asset="/content/dam/vyvgart/hcp/enroll-patients/ep_online-icon.svg" id="image-42389e9787" class="cmp-image" itemscope itemtype="http://schema.org/ImageObject"> 769 770 771 772 <img src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_257896284/container/container/teaser_new_rte_v2.coreimg.svg/1779913738993/ep-online-icon.svg" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt/> 773 774 775 776 777 778</div> 779 780 781 782</div> 783 784 <div class="cmp-teaser__content"> 785 786 787 788 789 <div class="cmp-teaser__title"> 790 <a class="cmp-teaser__title-link" href="https://mypathenroll.com/"><p>Online enrollment</p> 791</a> 792 </div> 793 794 795 <div class="cmp-teaser__description"><p>Fill out and submit the My VYVGART Path enrollment form online at <b><a href="https://mypathenroll.com/" target="_blank" style=" color: white; 796" rel="noopener noreferrer">MyPathEnroll.com</a></b></p> 797</div> 798 799 800 801 802 <div class="cmp-teaser__action-container"> 803 804 805 <a class="cmp-teaser__action-link " href="https://mypathenroll.com/" target="_self">Enroll today</a> 806 807 808 </div> 809 810 </div> 811</div> 812 813 814 815</div> 816<div class="teaser-new-rte-v2 teaser vyvgarthcp-button--primary vyvgarthcp-button--rounded-r4 vyv-teaser-image-auto-resize vyv-teaser-image-center-x aem-GridColumn--small--none aem-GridColumn--offset--xsmall--0 aem-GridColumn--default--none aem-GridColumn--xsmall--12 aem-GridColumn--xsmall--none aem-GridColumn aem-GridColumn--small--12 aem-GridColumn--offset--small--0 aem-GridColumn--default--6 aem-GridColumn--offset--default--0"> 817<div id="teaser-new-rte-v2-267d399af2" class="cmp-teaser"> 818 819 <div class="cmp-teaser__image"> 820<div data-cmp-is="image" data-cmp-lazythreshold="0" data-cmp-src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_257896284/container/container/teaser_new_rte_v2_co.coreimg{.width}.svg/1779913739083/ep-fax-icon.svg" data-asset="/content/dam/vyvgart/hcp/enroll-patients/ep_fax-icon.svg" id="image-267d399af2" class="cmp-image" itemscope itemtype="http://schema.org/ImageObject"> 821 822 823 824 <img src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_257896284/container/container/teaser_new_rte_v2_co.coreimg.svg/1779913739083/ep-fax-icon.svg" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt/> 825 826 827 828 829 830</div> 831 832 833 834</div> 835 836 <div class="cmp-teaser__content"> 837 838 839 840 841 <div class="cmp-teaser__title"> 842 <a class="cmp-teaser__title-link" href="/content/dam/vyvgart/hcp/pdfs/my-vyvgart-path-enrollment-form.pdf"><p>Enrollment via fax</p> 843</a> 844 </div> 845 846 847 <div class="cmp-teaser__description"><p>Download the enrollment form and fax the completed document to <b>1-833-698-7284</b></p> 848</div> 849 850 851 852 853 <div class="cmp-teaser__action-container"> 854 855 856 <a class="cmp-teaser__action-link " href="/content/dam/vyvgart/hcp/pdfs/my-vyvgart-path-enrollment-form.pdf.html" target="_self">Download form</a> 857 858 859 </div> 860 861 </div> 862</div> 863 864 865 866</div> 867 868 869</div> 870 871 </div> 872 873 874</div> 875<div class="text vyvgarthcp-text--small vyv-spacing--top-sm-8 vyv-spacing--top-sm-5"> 876<div id="text-b493d2d1f7" class="cmp-text"> 877 <p class="vyvgarthcp-text--footnote">*"All gMG serotypes" refers to antiâAChR-Ab positive, antiâMuSK-Ab positive, antiâLRP4-Ab positive, or triple seronegative.<sup>1,2 </sup><br /> 878Triple seronegative=anti-AChR, anti-MuSK, and anti-LRP4 antibodies negative.<sup>1,2<br /> 879 </sup>AChR-Ab=acetylcholine receptor antibody; gMG=generalized myasthenia gravis; LRP4-Ab=low-density lipoprotein receptor-related protein 4 antibody; MuSK-Ab=muscle-specific tyrosine ⨠kinase antibody.</p> 880 881</div> 882 883 884 885</div> 886 887 888 </div> 889 890</div> 891 892 893 </div> 894 895</div> 896<div class="container responsivegrid vyvgarthcp-container--section-gutter"> 897 898 899 900 901 <div id="key-details" class="cmp-container"> 902 903 <div class="text vyvgarthcp-color--primary vyv-spacing--bottom-sm-10"> 904<div id="text-44e8ed7f3c" class="cmp-text"> 905 <h2 style=" text-align: center; 906">Key details about the enrollment process</h2> 907 908</div> 909 910 911 912</div> 913<div class="container responsivegrid vyvgarthcp-container--group flex _items-stretch reset-flex--mobile vyv-spacing--bottom-sm-10"> 914 915 916 <div id="container-a589892a08" class="cmp-container"> 917 918 919 920<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 aem-Grid--xsmall--12 "> 921
922 <div class="teaser-new-rte-v2 teaser vyvgarthcp-teaser-rte--card vyv-spacing--bottom-sm-6 vyvgarthcp-spacing--desktop-bottom--none __cta-anchor--bottom vyv-teaser--rounded-3 vyv-teaser-theme--aqua-to-lt-purple vyv-teaser--padding-lg aem-GridColumn--offset--xsmall--0 aem-GridColumn--xsmall--12 aem-GridColumn--xsmall--none aem-GridColumn aem-GridColumn--default--12"> 923<div id="teaser-new-rte-v2-ce11f70ad0" class="cmp-teaser"> 924 925 926 927 <div class="cmp-teaser__content"> 928 929 930 931 932 <div class="cmp-teaser__title"> 933 <a class="cmp-teaser__title-link" href="/gmg/access/patient-support-program"><h3>My VYVGART Path</h3> 934</a> 935 </div> 936 937 938 <div class="cmp-teaser__description"><p>Learn more about how our comprehensive patient support program can help you and your patients.</p> 939</div> 940 941 942 943 944 <div class="cmp-teaser__action-container"> 945 946 947 <a class="cmp-teaser__action-link " href="/gmg/access/patient-support-program" target="_self">Get the details</a> 948 949 950 </div> 951 952 </div> 953</div> 954 955 956 957</div> 958<div class="teaser-new-rte-v2 teaser vyvgarthcp-teaser-rte--card vyv-spacing--bottom-sm-6 vyvgarthcp-spacing--desktop-bottom--none __cta-anchor--bottom vyv-teaser--rounded-3 vyv-teaser-theme--aqua-to-lt-purple vyv-teaser--padding-lg aem-GridColumn--offset--xsmall--0 aem-GridColumn--xsmall--12 aem-GridColumn--xsmall--none aem-GridColumn aem-GridColumn--default--12"> 959<div id="teaser-new-rte-v2-37d07050d0" class="cmp-teaser"> 960 961 962 963 <div class="cmp-teaser__content"> 964 965 966 967 968 <div class="cmp-teaser__title"> 969 <a class="cmp-teaser__title-link" href="/content/dam/vyvgart/hcp/pdfs/gMG-VYVGART-and-VYVGART-Hytrulo-Billing-and-Coding-Guide.pdf"><h3>Billing & coding</h3> 970</a> 971 </div> 972 973 974 <div class="cmp-teaser__description"><p>For <b>VYVGART Hytrulo</b>, use HCPCS J-Code <b>J9334</b> (injection, efgartigimod alfa 2 mg and hyaluronidase-qvfc). For <b>VYVGART</b>, use HCPCS J-Code <b>J9332</b> (injection, efgartigimod alfa-fcab 2 mg). <b>Do not use</b> J9332 for VYVGART Hytrulo.</p> 975<p>Â </p> 976<p>Â </p> 977</div> 978 979 980 981 982 <div class="cmp-teaser__action-container"> 983 984 985 <a class="cmp-teaser__action-link " href="/content/dam/vyvgart/hcp/pdfs/gMG-VYVGART-and-VYVGART-Hytrulo-Billing-and-Coding-Guide.pdf.html" target="_self">Download the Billing and Coding Guide for VYVGART Hytrulo or VYVGART for IV infusion</a> 986 987 988 </div> 989 990 </div> 991</div> 992 993 994 995</div> 996<div class="teaser-new-rte-v2 teaser vyvgarthcp-teaser-rte--card __cta-anchor--bottom vyv-teaser--rounded-3 vyv-teaser-theme--aqua-to-lt-purple vyv-teaser--padding-lg aem-GridColumn--offset--xsmall--0 aem-GridColumn--xsmall--12 aem-GridColumn--xsmall--none aem-GridColumn aem-GridColumn--default--12"> 997<div id="teaser-new-rte-v2-d860774939" class="cmp-teaser"> 998 999 1000 1001 <div class="cmp-teaser__content"> 1002 1003 1004 1005 1006 <div class="cmp-teaser__title"> 1007 <a class="cmp-teaser__title-link" href="/gmg/access/access-information#co-pay"><h3>VYVGART Co-pay Program</h3> 1008</a> 1009 </div> 1010 1011 1012 <div class="cmp-teaser__description"><p>Your patients could be eligible to save on their treatment with <b>VYVGART Hytrulo</b> or <b>VYVGART</b>.</p> 1013</div> 1014 1015 1016 1017 1018 <div class="cmp-teaser__action-container"> 1019 1020 1021 <a class="cmp-teaser__action-link " href="/gmg/access/access-information#co-pay" target="_self">Find savings</a> 1022 1023 1024 </div> 1025 1026 </div> 1027</div> 1028 1029 1030 1031</div> 1032 1033 1034</div> 1035 1036 </div> 1037 1038 1039</div> 1040<div class="text vyvgarthcp-text--small vyv-spacing--top-sm-3"> 1041<div id="text-66723421fe" class="cmp-text"> 1042 <p style=" text-align: center; 1043">HCPCS=Healthcare Common Procedure Coding System.</p> 1044 1045</div> 1046 1047 1048 1049</div> 1050 1051 1052 </div> 1053 1054</div> 1055<div class="container responsivegrid vyvgarthcp-container--fullbleed -padding-sm-9"> 1056 1057 1058 1059 1060 <div id="container-798e24a725" class="cmp-container" style="background-color:#E7F6F5;"> 1061 1062 <div class="container responsivegrid vyvgarthcp-container--content-gutter flex _items-center reset-flex--mobile"> 1063 1064 1065 <div id="container-f860a3cf1e" class="cmp-container"> 1066 1067 1068 1069<div class="aem-Grid aem-Grid--12 aem-Grid--small--12 aem-Grid--default--12 aem-Grid--xsmall--12 "> 1070 1071 <div class="text vyvgarthcp-color--primary vyv-spacing--bottom-sm-5 vyvgarthcp-spacing--desktop-bottom--none vyvgarthcp-text--center-mobile aem-GridColumn--small--none aem-GridColumn--offset--xsmall--0 aem-GridColumn--default--none aem-GridColumn--xsmall--12 aem-GridColumn--xsmall--none aem-GridColumn aem-GridColumn--small--12 aem-GridColumn--offset--small--0 aem-GridColumn--default--5 aem-GridColumn--offset--default--0"> 1072<div id="text-268c01df46" class="cmp-text"> 1073 <h3>Need support?</h3> 1074 1075</div> 1076 1077 1078 1079</div> 1080<div class="text vyvgarthcp-color--primary vyvgarthcp-text--center-mobile vyvgarthcp-text--wrap-pretty aem-GridColumn--small--none aem-GridColumn--offset--xsmall--0 aem-GridColumn--default--none aem-GridColumn--xsmall--12 aem-GridColumn--xsmall--none aem-GridColumn aem-GridColumn--small--12 aem-GridColumn--offset--small--0 aem-GridColumn--default--6 aem-GridColumn--offset--default--1"> 1081<div id="text-5080460aa1" class="cmp-text"> 1082 <p>Contact My VYVGART Path at <b>1-833-697-2841</b> for assistance for your patients who are on <b>VYVGART Hytrulo</b> or <b>VYVGART</b>.</p> 1083 1084</div> 1085 1086 1087 1088</div> 1089 1090 1091</div> 1092 1093 </div> 1094 1095 1096</div> 1097 1098 1099 </div> 1100 1101</div> 1102<div class="container responsivegrid vyvgarthcp-container--fullbleed vyv-theme--deep-nav
1102y-gradient"> 1103 1104 1105 1106 1107 <div id="container-239119cbcd" class="cmp-container"> 1108 1109 <div class="container responsivegrid vyvgarthcp-container--content-gutter"> 1110 1111 1112 1113 1114 <div id="container-6b5b41936a" class="cmp-container"> 1115 1116 <div class="text vyvgarthcp-color--white vyv-spacing--bottom-sm-8"> 1117<div id="text-b011274fb0" class="cmp-text"> 1118 <h2>Considerations for starting and staying on treatment</h2> 1119 1120</div> 1121 1122 1123 1124</div> 1125<div class="teaser-new-rte teaser vyvgarthcp-spacing--bottom-medium vyvgarthcp-teaser-rte--theme-white vyv-teaser-layout--horizontal vyv-teaser-layout--vertical-mobile vyv-teaser-image-auto-resize vyv-teaser-image-center-x vyvgarthcp-teaser--desc-textalign-center-mobile"> 1126<div id="teaser-new-rte-bc2cc80d41" class="cmp-teaser"> 1127 1128 <div class="cmp-teaser__image"> 1129<div data-cmp-is="image" data-cmp-lazythreshold="0" data-cmp-src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1868349668/container/teaser_new_rte_copy.coreimg{.width}.svg/1779913739660/ep-checkmark-icon.svg" data-asset="/content/dam/vyvgart/hcp/enroll-patients/ep_checkmark-icon.svg" id="image-bc2cc80d41" class="cmp-image" itemscope itemtype="http://schema.org/ImageObject"> 1130 1131 1132 1133 <img src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1868349668/container/teaser_new_rte_copy.coreimg.svg/1779913739660/ep-checkmark-icon.svg" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt/> 1134 1135 1136 1137 1138 1139</div> 1140 1141 1142 1143</div> 1144 1145 <div class="cmp-teaser__content"> 1146 1147 1148 1149 1150 <h2 class="cmp-teaser__title"> 1151 <p><b>MG-ADL assessments</b></p> 1152 1153 </h2> 1154 1155 1156 <div class="cmp-teaser__description"><p>Share the MG-ADL scale and partner with patients to establish their baseline total score at the start of therapy, then track changes over time to supp
1156ort ongoing treatment management</p> 1157</div> 1158 1159 1160 1161 1162 1163 1164 </div> 1165</div> 1166 1167 1168 1169</div> 1170<div class="teaser-new-rte teaser vyvgarthcp-spacing--bottom-medium vyvgarthcp-teaser-rte--theme-white vyv-teaser-layout--horizontal vyv-teaser-layout--vertical-mobile vyv-teaser-image-auto-resize vyv-teaser-image-center-x vyvgarthcp-teaser--desc-textalign-center-mobile"> 1171<div id="teaser-new-rte-98826b2f1a" class="cmp-teaser"> 1172 1173 <div class="cmp-teaser__image"> 1174<div data-cmp-is="image" data-cmp-lazythreshold="0" data-cmp-src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1868349668/container/teaser_new_rte_copy_.coreimg{.width}.svg/1779913739676/ep-chat-icon.svg" data-asset="/content/dam/vyvgart/hcp/enroll-patients/ep_chat-icon.svg" id="image-98826b2f1a" class="cmp-image" itemscope itemtype="http://schema.org/ImageObject"> 1175 1176 1177 1178 <img src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1868349668/container/teaser_new_rte_copy_.coreimg.svg/1779913739676/ep-chat-icon.svg" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt/> 1179 1180 1181 1182 1183 1184</div> 1185 1186 1187 1188</div> 1189 1190 <div class="cmp-teaser__content"> 1191 1192 1193 1194 1195 <h2 class="cmp-teaser__title"> 1196 <p><b>Patient counseling information</b></p> 1197 1198 </h2> 1199 1200 1201 <div class="cmp-teaser__description"><p>Discuss the risks of infections, hypersensitivity reactions, and infusion- or injection-related reactions associated with initiating therapy and ongoing treatment*</p> 1202</div> 1203 1204 1205 1206 1207 1208 1209 </div> 1210</div> 1211 1212 1213 1214</div> 1215<div class="teaser-new-rte teaser vyvgarthcp-spacing--bottom-medium vyvgarthcp-teaser-rte--theme-white vyv-teaser-layout--horizontal vyv-teaser-layout--vertical-mobile vyv-teaser-image-auto-resize vyv-teaser-image-center-x vyvgarthcp-teaser--desc-textalign-center-mobile"> 1216<div id="teaser-new-rte-494886ee59" class="cmp-teaser"> 1217 1218 <div class="cmp-teaser__image"> 1219<div data-cmp-is="image" data-cmp-lazythreshold="0" data-cmp-src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1868349668/container/teaser_new_rte_copy__1519434799.coreimg{.width}.svg/1779913739696/ep-medical-icon.svg" data-asset="/content/dam/vyvgart/hcp/enroll-patients/ep_medical-icon.svg" id="image-494886ee59" class="cmp-image" itemscope itemtype="http://schema.org/ImageObject"> 1220 1221 1222 1223 <img src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1868349668/container/teaser_new_rte_copy__1519434799.coreimg.svg/1779913739696/ep-medical-icon.svg" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt/> 1224 1225 1226 1227 1228 1229</div> 1230 1231 1232 1233</div> 1234 1235 <div class="cmp-teaser__content"> 1236 1237 1238 1239 1240 <h2 class="cmp-teaser__title"> 1241 <p><b>Sites of care</b></p> 1242 1243 </h2> 1244 1245 1246 <div class="cmp-teaser__description"><p>Review options for administration to understand patient needs and preferences</p> 1247</div> 1248 1249 1250 1251 1252 1253 1254 </div> 1255</div> 1256 1257 1258 1259</div> 1260<div class="teaser-new-rte-v2 teaser vyv-spacing--bottom-sm-8 vyv-teaser-layout--horizontal vyv-teaser-layout--vertical-mobile vyv-teaser-image-auto-resize vyv-teaser-image-center-x vyv-teaser-text-center-x-mobile"> 1261<div id="teaser-new-rte-v2-269371e240" class="cmp-teaser"> 1262 1263 <div class="cmp-teaser__image"> 1264<div data-cmp-is="image" data-cmp-lazythreshold="0" data-cmp-src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1868349668/container/teaser_new_rte_v2.coreimg{.width}.svg/1779913739711/ep-calendar-icon.svg" data-asset="/content/dam/vyvgart/hcp/enroll-patients/ep_calendar-icon.svg" id="image-269371e240" class="cmp-image" itemscope itemtype="http://schema.org/ImageObject"> 1265 1266 1267 1268 <img src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1868349668/container/teaser_new_rte_v2.coreimg.svg/1779913739711/ep-calendar-icon.svg" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt/> 1269 1270 1271 1272 1273 1274</div> 1275 1276 1277 1278</div> 1279 1280 <div class="cmp-teaser__content"> 1281 1282 1283 1284 1285 <div class="cmp-teaser__title"> 1286 <p><b>Access to multiple treatment cycles</b></p> 1287 1288 </div> 1289 1290 1291 <div class="cmp-teaser__description"><p>Initial authorization may allow for multiple treatment cycles for the majority of patients</p> 1292</div> 1293 1294 1295 1296 1297 1298 1299 </div> 1300</div> 1301 1302 1303 1304</div> 1305<div class="teaser-new-rte teaser vyvgarthcp-spacing--bottom-medium vyvgarthcp-teaser
1305-rte--theme-white vyv-teaser-layout--horizontal vyv-teaser-layout--vertical-mobile vyv-teaser-image-auto-resize vyv-teaser-image-center-x vyvgarthcp-teaser--desc-textalign-center-mobile"> 1306<div id="teaser-new-rte-e8a6c7d368" class="cmp-teaser"> 1307 1308 <div class="cmp-teaser__image"> 1309<div data-cmp-is="image" data-cmp-lazythreshold="0" data-cmp-src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1868349668/container/teaser_new_rte_copy__1576980065.coreimg{.width}.svg/1779913739726/ep-syringe-icon.svg" data-asset="/content/dam/vyvgart/hcp/enroll-patients/ep_syringe-icon.svg" id="image-e8a6c7d368" class="cmp-image" itemscope itemtype="http://schema.org/ImageObject"> 1310 1311 1312 1313 <img src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1868349668/container/teaser_new_rte_copy__1576980065.coreimg.svg/1779913739726/ep-syringe-icon.svg" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt/> 1314 1315 1316 1317 1318 1319</div> 1320 1321 1322 1323</div> 1324 1325 <div class="cmp-teaser__content"> 1326 1327 1328 1329 1330 <h2 class="cmp-teaser__title"> 1331 <p><b>No treatment-specific vaccinations are required for treatment</b><sup><b>1,2</b></sup></p> 1332 1333 </h2> 1334 1335 1336 <div class="cmp-teaser__description"><p>Evaluate the need for age-appropriate vaccines according to immunization guidelines before start of a treatment cycle with <span class="vyvgarthcp-color--aqua"><b>VYVGART<sup>â </sup></b></span></p> 1337</div> 1338 1339 1340 1341 1342 1343 1344 </div> 1345</div> 1346 1347 1348 1349</div> 1350<div class="teaser-new-rte teaser vyvgarthcp-spacing--bottom-medium vyvgarthcp-teaser-rte--theme-white vyv-teaser-layout--horizontal vyv-teaser-layout--vertical-mobile vyv-teaser-image-auto-resize vyv-teaser-image-center-x vyvgarthcp-teaser--desc-textalign-center-mobile"> 1351<div id="teaser-new-rte-757112aff9" class="cmp-teaser"> 1352 1353 <div class="cmp-teaser__image"> 1354<div data-cmp-is="image" data-cmp-lazythreshold="0" data-cmp-src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1868349668/container/teaser_new_rte_copy__1135262305.coreimg{.width}.svg/1779913739742/ep-certification-icon.svg" data-asset="/content/dam/vyvgart/hcp/enroll-patients/ep_certification-icon.svg" id="image-757112aff9" class="cmp-image" itemscope itemtype="http://schema.org/ImageObject"> 1355 1356 1357 1358 <img src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1868349668/container/teaser_new_rte_copy__1135262305.coreimg.svg/1779913739742/ep-certification-icon.svg" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt/> 1359 1360 1361 1362 1363 1364</div> 1365 1366 1367 1368</div> 1369 1370 <div class="cmp-teaser__content"> 1371 1372 1373 1374 1375 <h2 class="cmp-teaser__title"> 1376 <p><b>No REMS required</b></p> 1377 1378 </h2> 1379 1380 1381 <div class="cmp-teaser__description"><p><b class="vyvgarthcp-color--aqua">VYVGART</b> does not require any specific training or certification prior to starting treatment at this time</p> 1382</div> 1383 1384 1385 1386 1387 1388 1389 </div> 1390</div> 1391 1392 1393 1394</div> 1395<div class="teaser-new-rte teaser vyvgarthcp-spacing--bottom-medium vyvgarthcp-teaser-rte--theme-white vyv-teaser-layout--horizontal vyv-teaser-layout--vertical-mobile vyv-teaser-image-auto-resize vyv-teaser-image-center-x vyvgarthcp-teaser--desc-textalign-center-mobile"> 1396<div id="teaser-new-rte-791f5b5621" class="cmp-teaser"> 1397 1398 <div class="cmp-teaser__image"> 1399<div data-cmp-is="image" data-cmp-lazythreshold="0" data-cmp-src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1868349668/container/teaser_new_rte_copy__544052684.coreimg{.width}.svg/1779913739757/ep-no-routine-icon.svg" data-asset="/content/dam/vyvgart/hcp/enroll-patients/ep_no_routine-icon.svg" id="image-791f5b5621" class="cmp-image" itemscope itemtype="http://schema.org/ImageObject"> 1400 1401 1402 1403 <img src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1868349668/container/teaser_new_rte_copy__544052684.coreimg.svg/1779913739757/ep-no-routine-icon.svg" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt/> 1404 1405 1406 1407 1408 1409</div> 1410 1411 1412 1413</div> 1414 1415 <div class="cmp-teaser__content"> 1416 1417 1418 1419 1420 <h2 class="cmp-teaser__title"> 1421 <p><b>No routine lab monitoring required</b></p> 1422 1423 </h2> 1424 1425 1426 <div class="cmp-teaser__description"><p>There are no routine lab monitoring requirements for patients during treatment with <b class="vyvgarthcp-color--aqua">VYVGART</b>. Continue to evaluate response and monitor patients for possible side effects<sup>â¡</sup></p> 1427</div> 1428 1429 1430 1431 1432 1433 1434 </div> 1435</div> 1436 1437 1438 1439</div> 1440<div class="teaser-new-rte teaser vyvgarthcp-spacing--bottom-small vyvgarthcp-teaser
1440-rte--theme-white vyv-teaser-layout--horizontal vyv-teaser-layout--vertical-mobile vyv-teaser-image-auto-resize vyv-teaser-image-center-x vyvgarthcp-teaser--desc-textalign-center-mobile"> 1441<div id="teaser-new-rte-4c41f9c7c5" class="cmp-teaser"> 1442 1443 <div class="cmp-teaser__image"> 1444<div data-cmp-is="image" data-cmp-lazythreshold="0" data-cmp-src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1868349668/container/teaser_new_rte_copy__1233999702.coreimg{.width}.svg/1779913739772/ep-warning-icon.svg" data-asset="/content/dam/vyvgart/hcp/enroll-patients/ep_warning-icon.svg" id="image-4c41f9c7c5" class="cmp-image" itemscope itemtype="http://schema.org/ImageObject"> 1445 1446 1447 1448 <img src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1868349668/container/teaser_new_rte_copy__1233999702.coreimg.svg/1779913739772/ep-warning-icon.svg" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt/> 1449 1450 1451 1452 1453 1454</div> 1455 1456 1457 1458</div> 1459 1460 <div class="cmp-teaser__content"> 1461 1462 1463 1464 1465 <h2 class="cmp-teaser__title"> 1466 <p><b>No Boxed Warning</b></p> 1467 1468 </h2> 1469 1470 1471 <div class="cmp-teaser__description"><p>Please see the full Prescribing Information for <b class="vyvgarthcp-color--lavender-fields">VYVGART Hytrulo</b> and <b class="vyvgarthcp-color--aqua">VYVGART</b> before starting patients on treatment</p> 1472</div> 1473 1474 1475 1476 1477 1478 1479 </div> 1480</div> 1481 1482 1483 1484</div> 1485<div class="text vyvgarthcp-color--white"> 1486<div id="text-9952bc1b38" class="cmp-text"> 1487 <p class="vyvgarthcp-text--footnote">*Please also see the Patient Counseling Information in Section 17 of the Prescribing Information.</p> 1488<p class="vyvgarthcp-text--footnote"><sup>â </sup>In accordance with the recommendations found in Section 2.1 of the Prescribing Information.â¨</p> 1489<p class="vyvgarthcp-text--footnote"><sup>â¡</sup>Patients in the ADAPT-SC and ADAPT clinical trials were required to have IgG levels of at least 6 g/L at study entry. Please also see the Warnings and Precautions found in Section 5 of the Prescribing Information.<sup>1,2</sup></p> 1490<p class="vyvgarthcp-text--footnote">VYVGART refers collectively to VYVGART Hytrulo for subcutaneous injection and VYVGART for intravenous infusion.<sup>1,2 </sup><br /> 1491</p> 1492<p class="vyvgarthcp-text--footnote">IgG=immunoglobulin G; MG-ADL=Myasthenia Gravis Activities of Daily Living; REMS=Risk Evaluation and Mitigation Strategy.</p> 1493 1494</div> 1495 1496 1497 1498</div> 1499 1500 1501 </div> 1502 1503</div> 1504 1505 1506 </div> 1507 1508</div> 1509<div class="container responsivegrid"> 1510 1511 1512 1513 1514 <div id="enrollment-support" class="cmp-container"> 1515 1516 <div class="container responsivegrid vyvgarthcp-container--section-gutter"> 1517 1518 1519 1520 1521 <div id="enroll-ico-section" class="cmp-container"> 1522 1523 <div class="container responsivegrid vyv-spacing--bottom-sm-9"> 1524 1525 1526 1527 1528 <div id="container-8a26dc0b9f" class="cmp-container"> 1529 1530 <div class="text vyv-spacing--bottom-sm-3 vyv-spacing--bottom-sm-4"> 1531<div id="text-d9b6308b1b" class="cmp-text"> 1532 <h2 style=" text-align: center; 1533">Enrollment support for you and your practice</h2> 1534 1535</div> 1536 1537 1538 1539</div> 1540 1541 1542 </div> 1543 1544</div> 1545<div class="container responsivegrid"> 1546 1547 1548 <div id="container-902294d04c" class="cmp-container"> 1549 1550 1551 1552<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 "> 1553 1554 <div class="container responsivegrid vyvgarthcp-container--group vyv-spacing--bottom-sm-8 aem-GridColumn aem-GridColumn--default--12"> 1555 1556 1557 <div id="container-8d9f3dc078" class="cmp-container"> 1558 1559 1560 1561<div class="aem-Grid aem-Grid--12 aem-Grid--small--12 aem-Grid--default--12 aem-Grid--xsmall--12 "> 1562 1563 <div class="teaser-new-rte teaser vyvgarthcp-teaser-rte--card vyvgarthcp-spacing--bottom-small vyvgarthcp-spacing--desktop-bottom--none vyvgarthcp-teaser-rte--theme-primary __vertical-center-mobile aem-GridColumn--small--none aem-GridColumn--offset--xsmall--0 aem-GridColumn--default--none aem-GridColumn--xsmall--12 aem-GridColumn--xsmall--none aem-GridColumn aem-GridColumn--small--12 aem-GridColumn--offset--small--0 aem-GridColumn--default--6 aem-GridColumn--offset--default--0"> 1564<div id="teaser-new-rte-5b30045373" class="cmp-teaser"> 1565 1566 <div class="cmp-teaser__image"> 1567<div data-cmp-is="image" data-cmp-lazythreshold="0" data-cmp-src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1828189094/container/container/container_1634477729_1018510281/teaser_new_rte_copy_.coreimg.90{.width}.png/1779913739906/enrollment-form.png" data-cmp-widths="768,1200,1440,1980" data-asset="/content/dam/vyvgart/hcp/resources/video-library-thumbn
1567ails/enrollment-form.png" id="image-5b30045373" class="cmp-image" itemscope itemtype="http://schema.org/ImageObject"> 1568 <a class="cmp-image__link" href="/content/dam/vyvgart/hcp/pdfs/my-vyvgart-path-enrollment-form.pdf" data-cmp-hook-image="link"> 1569 <noscript data-cmp-hook-image="noscript"> 1570 1571 <img src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1828189094/container/container/container_1634477729_1018510281/teaser_new_rte_copy_.coreimg.png/1779913739906/enrollment-form.png" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt/> 1572 1573 </noscript> 1574 </a> 1575 1576 1577</div> 1578 1579 1580 1581</div> 1582 1583 <div class="cmp-teaser__content"> 1584 1585 1586 1587 1588 <h2 class="cmp-teaser__title"> 1589 <a class="cmp-teaser__title-link" href="/content/dam/vyvgart/hcp/pdfs/my-vyvgart-path-enrollment-form.pdf"><p><b>Enrollment Form</b></p> 1590</a> 1591 </h2> 1592 1593 1594 <div class="cmp-teaser__description"><p>Downloadable version of the VYVGART Hytrulo and VYVGART enrollment form to fill out and fax to get patients started on treatment and enrolled in My VYVGART Path.</p> 1595</div> 1596 1597 1598 1599 1600 1601 1602 </div> 1603</div> 1604 1605 1606 1607</div> 1608<div class="teaser-new-rte teaser vyvgarthcp-teaser-rte--card vyvgarthcp-teaser-rte--theme-primary __vertical-center-mobile aem-GridColumn--small--none aem-GridColumn--offset--xsmall--0 aem-GridColumn--default--none aem-GridColumn--xsmall--12 aem-GridColumn--xsmall--none aem-GridColumn aem-GridColumn--small--12 aem-GridColumn--offset--small--0 aem-GridColumn--default--6 aem-GridColumn--offset--default--0"> 1609<div id="teaser-new-rte-6b6ca9393c" class="cmp-teaser"> 1610 1611 <div class="cmp-teaser__image"> 1612<div data-cmp-is="image" data-cmp-lazythreshold="0" data-cmp-src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1828189094/container/container/container_1634477729_1018510281/teaser_new_rte_copy__8698319.coreimg.90{.width}.jpeg/1779913739974/spanish-enrollment-form-thumb.jpeg" data-cmp-widths="768,1200,1440,1980" data-asset="/content/dam/vyvgart/hcp/resources/video-library-thumbnails/spanish-enrollment-form-thumb.jpg" id="image-6b6ca9393c" class="cmp-image" itemscope itemtype="http://schema.org/ImageObject"> 1613 <a class="cmp-image__link" href="/content/dam/vyvgart/hcp/pdfs/PSP_Enrollment_Form_Spanish_PDF.pdf" data-cmp-hook-image="link"> 1614 <noscript data-cmp-hook-image="noscript"> 1615 1616 <img src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1828189094/container/container/container_1634477729_1018510281/teaser_new_rte_copy__8698319.coreimg.jpeg/1779913739974/spanish-enrollment-form-thumb.jpeg" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt/> 1617 1618 </noscript> 1619 </a> 1620 1621 1622</div> 1623 1624 1625 1626</div> 1627 1628 <div class="cmp-teaser__content"> 1629 1630 1631 1632 1633 <h2 class="cmp-teaser__title"> 1634 <a class="cmp-teaser__title-link" href="/content/dam/vyvgart/hcp/pdfs/PSP_Enrollment_Form_Spanish_PDF.pdf"><p><b>Spanish Enrollment Form</b></p> 1635</a> 1636 </h2> 1637 1638 1639 <div class="cmp-teaser__description"><p>Downloadable Spanish-language version of the VYVGART Hytrulo and VYVGART enrollment form to fill out and fax to get patients started on treatment and enrolled in My VYVGART Path.</p> 1640</div> 1641 1642 1643 1644 1645 1646 1647 </div> 1648</div> 1649 1650 1651 1652</div> 1653 1654 1655</div> 1656 1657 </div> 1658 1659 1660</div> 1661<div class="container responsivegrid vyvgarthcp-container--group container--reset-padding aem-GridColumn aem-GridColumn--default--12"> 1662 1663 1664 <div id="container-2fd8a9c410" class="cmp-container"> 1665 1666 1667 1668<div class="aem-Grid aem-Grid--12 aem-Grid--small--12 aem-Grid--default--12 aem-Grid--xsmall--12 "> 1669 1670 <div class="teaser-new-rte teaser vyvgarthcp-teaser-rte--card __title-color-deep-navy vyvgarthcp-spacing--bottom-small vyvgarthcp-spacing--desktop-bottom--none vyvgarthcp-teaser-rte--theme-primary __vertical-center-mobile aem-GridColumn--small--none aem-GridColumn--offset--xsmall--0 aem-GridColumn--default--none aem-GridColumn--xsmall--12 aem-GridColumn--xsmall--none aem-GridColumn aem-GridColumn--small--12 aem-GridColumn--offset--small--0 aem-GridColumn--default--6 aem-GridColumn--offset--default--0"> 1671<div id="teaser-new-rte-42fbad296a" class="cmp-teaser"> 1672 1673 <div class="cmp-teaser__image"> 1674<div data-cmp-is="image" data-cmp-lazythreshold="0" data-cmp-src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1828189094/container/container/container_1634477729_758183788/teaser_new_rte_copy_.coreimg.90{.width}.png/1779913740066/ep-hcp-my-vyvgart-path-overview-brochure-thumb.png" data-cmp-widths="768,1200,1440,1980" data-asset="/content/dam/vyvgart/hcp/enroll-patients/ep-hcp-my-vyvgart-path-overview-brochure-thumb.png" id="image-42fbad296a" class="cmp-image" itemscope itemtype="http://schema.org/ImageObject"> 1675 <a class="cmp-image__link" href="/content/dam/vyvgart/hcp/pdfs/SC-Update-PSP-Program-Overview-Brochure-HCP.pdf" data-cmp-hook-image="link"> 1676 <noscript data-cmp-hook-image="noscript"> 1677 1678 <img src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1828189094/container/container/container_1634477729_758183788/teaser_new_rte_copy_.coreimg.png/1779913740066/ep-hcp-my-vyvgart-path-overview-brochure-thumb.png" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt/> 1679 1680 </noscript> 1681 </a> 1682 1683 1684</div> 1685 1686 1687 1688</div> 1689 1690 <div class="cmp-teaser__content"> 1691 1692 1693 1694 1695 <h2 class="cmp-teaser__title"> 1696 <a class="cmp-teaser__title-link" href="/content/dam/vyvgart/hcp/pdfs/SC-Update-PSP-Program-Overview-Brochure-HCP.pdf"><p><b>My VYVGART Path HCP Overview Brochure</b></p> 1697</a> 1698 </h2> 1699 1700 1701 <div class="cmp-teaser__description"><p>An overview of support offerings for you and your patients through the My VYVGART Path program.</p> 1702</div> 1703 1704 1705 1706 1707 1708 1709 </div> 1710</div> 1711 1712 1713 1714</div>
1715<div class="teaser-new-rte teaser vyvgarthcp-teaser-rte--card vyvgarthcp-teaser-rte--theme-primary __vertical-center-mobile aem-GridColumn--small--none aem-GridColumn--offset--xsmall--0 aem-GridColumn--default--none aem-GridColumn--xsmall--12 aem-GridColumn--xsmall--none aem-GridColumn aem-GridColumn--small--12 aem-GridColumn--offset--small--0 aem-GridColumn--default--6 aem-GridColumn--offset--default--0"> 1716<div id="teaser-new-rte-502be11c1c" class="cmp-teaser"> 1717 1718 <div class="cmp-teaser__image"> 1719<div data-cmp-is="image" data-cmp-lazythreshold="0" data-cmp-src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1828189094/container/container/container_1634477729_758183788/teaser_new_rte_copy__8698319.coreimg.90{.width}.png/1779913740140/ep-prefilled-syringe-faqs-thumb.png" data-cmp-widths="768,1200,1440,1980" data-asset="/content/dam/vyvgart/hcp/enroll-patients/ep-prefilled-syringe-faqs-thumb.png" id="image-502be11c1c" class="cmp-image" itemscope itemtype="http://schema.org/ImageObject"> 1720 <a class="cmp-image__link" href="/content/dam/vyvgart/hcp/pdfs/VYVGART-Hytrulo-Prefilled-Syringe-FAQs.pdf" data-cmp-hook-image="link"> 1721 <noscript data-cmp-hook-image="noscript"> 1722 1723 <img src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1828189094/container/container/container_1634477729_758183788/teaser_new_rte_copy__8698319.coreimg.png/1779913740140/ep-prefilled-syringe-faqs-thumb.png" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt/> 1724 1725 </noscript> 1726 </a> 1727 1728 1729</div> 1730 1731 1732 1733</div> 1734 1735 <div class="cmp-teaser__content"> 1736 1737 1738 1739 1740 <h2 class="cmp-teaser__title"> 1741 <a class="cmp-teaser__title-link" href="/content/dam/vyvgart/hcp/pdfs/VYVGART-Hytrulo-Prefilled-Syringe-FAQs.pdf"><p><b>Prefilled Syringe FAQs</b></p> 1742</a> 1743 </h2> 1744 1745 1746 <div class="cmp-teaser__description"><p>A comprehensive downloadable resource addressing a wide range of frequently asked questions about the VYVGART Hytrulo single-dose prefilled syringe.</p> 1747</div> 1748 1749 1750 1751 1752 1753 1754 </div> 1755</div> 1756 1757 1758 1759</div> 1760 1761 1762</div> 1763 1764 </div> 1765 1766 1767</div> 1768 1769 1770</div> 1771 1772 </div> 1773 1774 1775</div> 1776<div class="container responsivegrid vyv-spacing--top-md-3"> 1777 1778 1779 1780 1781 <div id="container-0e6ac4cfbb" class="cmp-container"> 1782 1783 <div class="text vyvgarthcp-text--small"> 1784<div id="text-421fcbfdee" class="cmp-text"> 1785 <p>HCP=healthcare professional.</p> 1786 1787</div> 1788 1789 1790 1791</div> 1792 1793 1794 </div> 1795 1796</div> 1797 1798 1799 </div> 1800 1801</div> 1802 1803 1804 </div> 1805 1806</div> 1807<div class="container responsivegrid"> 1808 1809 1810 1811 1812 <div id="teaser-banner--text-vertical-tr" class="cmp-container"> 1813 1814 <div class="text vyvgarthcp-text--patient-portrayal-vertical-tr vyvgarthcp-color--white"> 1815<div id="text-8dbc5b8359" class="cmp-text"> 1816 <p>Patient portrayal</p> 1817 1818</div> 1819 1820 1821 1822</div> 1823 1824 1825 </div> 1826 1827</div> 1828<div class="container responsivegrid vyvgarthcp-container--fullbleed vyvgarthcp-container--section-gutter"> 1829 1830 1831 <div id="container-6592029475" class="cmp-container" style="background-color:#022A47;"> 1832 1833 1834 1835<div class="aem-Grid aem-Grid--12 aem-Grid--small--12 aem-Grid--default--12 aem-Grid--xsmall--12 "> 1836 1837 <div class="container responsivegrid vyvgarthcp-container--content-gutter aem-GridColumn--small--none aem-GridColumn--default--none aem-GridColumn--offset--xsmall--1 aem-GridColumn--small--10 aem-GridColumn--xsmall--none aem-GridColumn aem-GridColumn--offset--small--1 aem-GridColumn--default--8 aem-GridColumn--offset--default--2 aem-GridColumn--xsmall--10"> 1838 1839 1840 1841 1842 <div id="container-181afb9355" class="cmp-container"> 1843 1844 <div class="text vyvgarthcp-color--white vyv-spacing--bottom-sm-4"> 1845<div id="text-445535216d" class="cmp-text"> 1846 <h2 style=" text-align: center; 1847">Receive more information about both <b>VYVGART Hytrulo</b> and <b>VYVGART</b> for adult patients with gMG.</h2> 1848 1849</div> 1850 1851 1852 1853</div> 1854<div class="button vyvgarthcp-button--primary __text-align-center vyvgarthcp-button--rounded-r4"> 1855<a id="button-b16fb33dcf" class="cmp-button" href="#contact-a-rep" target="_self"> 1856 1857 1858 1859 <span class="cmp-button__text">Contact a rep</span> <!--Added context for the button text--> 1860</a> 1861</div> 1862<div class="text vyvgarthcp-text--small vyvgarthcp-color--white vyv-spacing--top-sm-4"> 1863<div id="text-7f1a81944d" class="cmp-text"> 1864 <p style=" text-align: center; 1865">gMG=generalized myasthenia gravis.</p> 1866 1867</div> 1868 1869 1870 1871</div> 1872 1873 1874 </div> 1875 1876</div> 1877 1878 1879</div> 1880 1881 </div> 1882 1883 1884</div> 1885 1886 1887 </div> 1888 1889</main> 1890<div class="container responsivegrid"> 1891 1892 1893 1894 1895 <div id="full-isi" class="cmp-container"> 1896 1897 <div class="fragment-importer"> 1898 1899 1900 <div class="xfpage page basicpage"> 1901 1902 1903 1904 <div id="container-109957fe89" class="cmp-container"> 1905 1906 1907 1908<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 "> 1909 1910 <div class="container responsivegrid vyvh-cidp--tray-container aem-GridColumn aem-GridColumn--default--12"> 1911 1912 1913 1914 1915 <div id="container-763edea7f3" class="cmp-container"> 1916 1917 <div class="tabs panelcontainer tabs-cidp tabs-cidp--tab-1-violet tabs-cidp--tab-2-teal"> 1918<div id="isi" class="cmp-tabs" data-cmp-is="tabs" data-placeholder-text="false"> 1919 <ol role="tablist" class="cmp-tabs__tablist" aria-multiselectable="false"> 1920 1921 <li role="tab" id="isi-item-0adbc7186a-tab" class="cmp-tabs__tab cmp-tabs__tab--active" aria-controls="isi-item-0adbc7186a-tabpanel" tabindex="0" data-cmp-hook-tabs="tab">VYVGART Hytrulo</li> 1922 1923 1924 <li role="tab" id="isi-item-1b4df2c8a8-tab" class="cmp-tabs__tab" aria-controls="isi-item-1b4df2c8a8-tabpanel" tabindex="-1" data-cmp-hook-tabs="tab">VYVGART</li> 1925 </ol> 1926 <div id="isi-item-0adbc7186a-tabpanel" role="tabpanel" aria-labelledby="isi-item-0adbc7186a-tab" tabindex="0" class="cmp-tabs__tabpanel cmp-tabs__tabpanel--active" data-cmp-hook-tabs="tabpanel" data-cmp-data-layer="{"isi-item-0adbc7186a":{"@type":"argenx/components/content/tabs/item","dc:title":"VYVGART Hytrulo"}}"><div class="container responsivegrid"> 1927 1928 1929 <div id="container-7bbd9fd6fe" class="cmp-container"> 1930 1931 1932 1933<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 "> 1934 1935 <div class="text vyv-text--isi vyvgarthcp-text--p-margin-bottom-xs aem-GridColumn aem-GridColumn--default--12"> 1936<div id="®" class="cmp-text"> 1937 <h4 class="br-none-mobile"><b>IMPORTANT SAFETY INFORMATION AND INDICATION</b></h4> 1938<h4 class="br-none-mobile"><b>CONTRAINDICATIONS</b></h4> 1939<p>VYVGART HYTRULO is contraindicated in patients with serious hypersensitivity to efgartigimod alfa products, to hyaluronidase, or to any of the excipients of VYVGART HYTRULO. Reactions have included anaphylaxis and hypotension leading to syncope. </p> 1940<h4><b>WARNINGS AND PRECAUTIONS<br /> 1941</b> <b>Infections</b></h4> 1942<p>VYVGART HYTRULO may increase the risk of infection. The most common infections observed in Study 1 were urinary tract infection (10% of efgartigimod alfa-fcab-treated patients vs 5% of placebo-treated patients) and respiratory tract infections (33% of efgartigimod alfa-fcab-treated patients vs 29% of placebo-treated patients). Patients on efgartigimod alfa-fcab vs placebo had below normal levels for white blood cell counts (12% vs 5%, respectively), lymphocyte counts (28% vs 19%, respectively), and neutrophil counts (13% vs 6%, respectively). The majority of infections and hematologic abnormalities were mild to moderate in severity. Delay VYVGART HYTRULO administration in patients with an active infection until the infection has resolved; monitor for clinical signs and symptoms of infections. If serious infection occurs, administer appropriate treatment and consider withholding VYVGART HYTRULO until the infection has resolved.</p> 1943<h4><b>Immunization</b></h4> 1944<p>Evaluate the need to administer age-appropriate vaccines according to immunization guidelines before initiation of a new treatment cycle with VYVGART HYTRULO. The safety of immunization with live vaccines and the immune response to vaccination during treatment with VYVGART HYTRULO are unknown. Because VYVGART HYTRULO causes a reduction in immunoglobulin G (IgG) levels, vaccination with live vaccines is not recommended during treatment with VYVGART HYTRULO.</p> 1945<h4><b>Hypersensitivity Reactions</b></h4> 1946<p>In clinical trials, hypersensitivity reactions, including rash, angioedema, and dyspnea were observed in patients treated with VYVGART HYTRULO or intravenous efgartigimod alfa-fcab. Urticaria was also observed in patients treated with VYVGART HYTRULO. Hypersensitivity reactions were mild or moderate, occurred within 1 hour to 3 weeks of administration. Anaphylaxis and hypotension leading to syncope have been reported in postmarketing experience with intravenous efgartigimod alfa-fcab. Anaphylaxis and hypotension occurred during or within an hour of administration and led to infusion discontinuation and in some cases to permanent treatment discontinuation. Monitor for clinical signs and symptoms of hypersensitivity reactions for at least 30 minutes after administration. If a hypersensitivity reaction occurs, the healthcare professional should institute appropriate measures if needed or the patient should seek medical attention.</p> 1947<h4><b>Infusion/Injection-Related Reactions </b></h4> 1948<p>Infusion-related reactions have been reported with intravenous efgartigimod alfa-fcab in postmarketing experience. The most frequent symptoms and signs were hypertension, chills, shivering, and thoracic, abdominal, and back pain. Infusion-related reactions occurred during or within an hour of administration and led to infusion discontinuation. If a severe infusion/injection-related reaction occurs, initiate appropriate therapy. Consider the risks and benefits of readministering VYVGART HYTRULO following a severe infusion/injection-related reaction. If a mild to moderate infusion/injection-related reaction occurs, patients may be rechallenged with close clinical observation, slower infusion/injection rates, and pre-medications.</p> 1949<h4><b>ADVERSE REACTIONS</b></h4> 1950<p>Patients with gMG: In Study 1, the most common (â¥10%) adverse reactions in efgartigimod alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. In Study 2, the overall safety profile was consistent with the known safety profile of efgartigimod alfa-fcab in patients with gMG, except for nausea, which occurred in 7% of anti-acetylcholine receptor (AChR) antibody negative patients who received efgartigimod alfa-fcab compared to 5% of patients who received placebo. In Study 3, the most common (â¥10%) adverse reactions in VYVGART HYTRULO- treated patients were injection site reactions and headache. Injection site reactions occurred in 38% of VYVGART HYTRULO-treated patients, including injection site rash, erythema, pruritus, bruising, pain, and urticaria. In Study 3 and its open-label extension, all injection site reactions were mild to moderate in severity and did not lead to treatment discontinuation. The majority occurred within 24 hours after administration and resolved spontaneously. Most injection site reactions occurred during the first treatment cycle, and the incidence decreased with each subsequent cycle.<br /> 1951<br /> 1952Patients with CIDP: In Study 4 stage B, the overall safety profile observed in patients with CIDP treated with VYVGART HYTRULO was consistent with the known safety profile of VYVGART HYTRULO and of efgartigimod alfa-fcab administered intravenously. In Study 4, injection site reactions occurred in 15% of patients treated with VYVGART HYTRULO compared to 6% of patients who received placebo. The most common of these injection site reactions were injection site bruising and injection site erythema. All injection site reactions were mild to moderate in severity. Most injection site reactions occurred during the first 3 months of treatment.</p> 1953<h4><b>USE IN SPECIFIC POPULATIONS<br /> 1954 Pregnancy<br /> 1955 </b><span style=" font-weight: 400; 1956">As VYVGART HYTRULO is expected to reduce maternal IgG antibody levels, reduction in passive protection to the newborn is anticipated. Risk and benefits should be considered prior to administering live vaccines to infants exposed to VYVGART HYTRULO in utero.</span></h4> 1957<h4> </h4> 1958<h4><b>Lactation<br /> 1959 </b><span style=" font-weight: 400; 1960">There is no information regarding the presence of efgartigimod alfa or hyaluronidase, from administration of VYVGART HYTRULO, in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the motherâs clinical need for VYVGART HYTRULO and any potential adverse effects on the breastfed infant from VYVGART HYTRULO or from the underlying maternal
1960condition.</span></h4> 1961<h4> </h4> 1962<h4><b>INDICATION<br /> 1963 </b><span style=" font-weight: 400; 1964">VYVGART HYTRULO<sup>®</sup> (efgartigimod alfa and hyaluronidase-qvfc) is indicated for the treatment of adult patients with:</span></h4> 1965<ul><li style=" text-align: left; 1966">generalized myasthenia gravis (gMG)</li><li style=" text-align: left; 1967">chronic inflammatory demyelinating polyneuropathy (CIDP)</li></ul> 1968<p> </p> 1969<p><b>Please see the full <a href="https://www.argenx.com/product/vyvgart-hytrulo-prescribing-information.pdf" target="_blank" rel="noopener noreferrer">Prescribing Information</a>.</b></p> 1970<p>You may report side effects to the US Food and Drug Administration by visiting <a href="https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program">http://www.fda.gov/medwatch</a> or calling 1-800-FDA-1088. You may also report side effects to argenx US, Inc, at 1-833-argx411 (1-833-274-9411).</p> 1971<p><b>Dosage Forms and Strengths:</b> VYVGART Hytrulo is available as a single-dose subcutaneous injection containing: 200 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per prefilled syringe, or 180 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per vial.</p> 1972 1973</div> 1974 1975 1976 1977</div> 1978 1979 1980</div> 1981 1982 </div> 1983 1984 1985</div> 1986</div> 1987<div id="isi-item-1b4df2c8a8-tabpanel" role="tabpanel" aria-labelledby="isi-item-1b4df2c8a8-tab" tabindex="0" class="cmp-tabs__tabpanel" data-cmp-hook-tabs="tabpanel" data-cmp-data-layer="{"isi-item-1b4df2c8a8":{"@type":"argenx/components/content/tabs/item","repo:modifyDate":"2026-05-27T18:20:51Z","dc:title":"VYVGART"}}"><div class="container responsivegrid"> 1988 1989 1990 1991 1992 <div id="container-fff6eb5077" class="cmp-container"> 1993 1994 <div class="text vyv-text--isi vyvgarthcp-text--p-margin-bottom-xs"> 1995<div id="text-0ff6c85701" class="cmp-text"> 1996 <h4 class="br-none-mobile"><b>IMPORTANT SAFETY INFORMATION AND INDICATION<br /> 1997 CONTRAINDICATIONS</b></h4> 1998<p>VYVGART is contraindicated in patients with serious hypersensitivity to efgartigimod alfa products or to any of the excipients of VYVGART. Reactions have included anaphylaxis and hypotension leading to syncope.</p> 1999<h4><b>WARNINGS AND PRECAUTIONS</b><br /> 2000<b>Infection</b></h4> 2001<p>VYVGART may increase the risk of infection. The most common infections observed in Study 1 were urinary tract infection (10% for VYVGART vs 5% for placebo) and respiratory tract infections (33% for VYVGART vs 29% for placebo). Patients on VYVGART vs placebo had below normal levels for white blood cell counts (12% vs 5%, respectively), lymphocyte counts (28% vs 19%, respectively), and neutrophil counts (13% vs 6%, respectively). The majority of infections and hematologic abnormalities were mild to moderate in severity. Delay VYVGART administration in patients with an active infection until the infection has resolved; monitor for clinical signs and symptoms of infections. If serious infection occurs, administer appropriate treatment and consider withholding VYVGART until the infection has resolved.</p> 2002<h4><b>Immunization</b></h4> 2003<p>Evaluate the need to administer age-appropriate vaccines according to immunization guidelines before initiation of a new treatment cycle with VYVGART. The safety of immunization with live vaccines and the immune response to vaccination during treatment with VYVGART are unknown. Because VYVGART causes a reduction in immunoglobulin G (IgG) levels, vaccination with live vaccines is not recommended during treatment with VYVGART.</p> 2004<h4><b>Hypersensitivity Reactions</b></h4> 2005<p>In clinical trials, hypersensitivity reactions, including rash, angioedema, and dyspnea were observed in VYVGART-treated patients. Hypersensitivity reactions were mild or moderate, occurred within 1 hour to 3 weeks of administration, and did not lead to treatment discontinuation. Anaphylaxis and hypotension leading to syncope have been reported in postmarketing experience with VYVGART. Anaphylaxis and hypotension occurred during or within an hour of administration and led to infusion discontinuation and in some cases to permanent treatment discontinuation. Monitor patients during administration and for 1 hour thereafter for clinical signs and symptoms of hypersensitivity reactions. If a hypersensitivity reaction occurs, the healthcare professional should institute appropriate measures if needed or the patient should seek medical attention.</p> 2006<h4><b>Infusion-Related Reactions</b></h4> 2007<p>Infusion-related reactions have been reported with VYVGART in postmarketing experience. The most frequent symptoms and signs were hypertension, chills, shivering, and thoracic, abdominal, and back pain. Infusion-related reactions occurred during or within an hour of administration and led to infusion discontinuation. If a severe infusion-related reaction occurs during administration, discontinue VYVGART infusion and initiate appropriate therapy. Consider the risks and benefits of readministering VYVGART following a severe infusion-related reaction. If a mild to moderate infusion-related reaction occurs, patients may be rechallenged with close clinical observation, slower infusion rates, and pre-medications.</p> 2008<h4><b>ADVERSE REACTIONS</b></h4> 2009<p>In Study 1, the most common (â¥10%) adverse reactions with VYVGART-treated patients were respiratory tract infection, headache, and urinary tract infection. In Study 2, the overall safety profile was consistent with the known safety profile of VYVGART in patients with gMG, except for nausea, which occurred in 7% of anti-acetylcholine receptor (AChR) antibody negative patients who received VYVGART compared to 5% of patients who received placebo.</p> 2010<h4><b>USE IN SPECIFIC POPULATIONS</b><br /> 2011<b>Pregnancy</b></h4> 2012<p>As VYVGART is expected to reduce maternal IgG antibody levels, reduction in passive protection to the newborn is anticipated. Risk and benefits should be considered prior to administering live vaccines to infants exposed to VYVGART in utero.</p> 2013<h4><b>Lactation</b></h4> 2014<p>There is no information regarding the presence of efgartigimod alfa-fcab in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the motherâs clinical need for VYVGART and any potential adverse effects on the breastfed infant from VYVGART or from the underlying maternal
2014condition.</p> 2015<h4 id="indication"><b>INDICATION</b></h4> 2016<p>VYVGART® (efgartigimod alfa-fcab) is indicated for the treatment of adult patients with generalized myasthenia gravis (gMG).</p> 2017<p><b>Please see the full <a href="https://www.argenx.com/product/vyvgart-prescribing-information.pdf">Prescribing Information</a>.</b></p> 2018<p>You may report side effects to the US Food and Drug Administration by visiting <a href="https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program">http://www.fda.gov/medwatch</a> or calling 1-800-FDA-1088. You may also report side effects to argenx US, Inc, at 1-833-argx411 (1-833-274-9411).</p> 2019<p><b>Dosage Form and Strength:</b> VYVGART is available as a single-dose injection for intravenous use containing 400 mg/20 mL of efgartigimod alfa-fcab per vial.</p> 2020 2021</div> 2022 2023 2024 2025</div> 2026 2027 2028 </div> 2029 2030</div> 2031</div> 2032 2033 2034</div> 2035</div> 2036<div class="container responsivegrid vyvh-cidp-tray"> 2037 2038 2039 2040 2041 <div id="container-d2ec71ac59" class="cmp-container"> 2042 2043 <div class="button vyvh-cidp--exapnd-btn"> 2044<button type="button" id="button-b53fd10e34" class="cmp-button" target="_self"> 2045 2046 2047 2048 <!--Added context for the button text--> 2049</button> 2050</div> 2051<div class="tabs panelcontainer tabs-cidp tabs-cidp--tab-1-violet tabs-cidp--tab-2-teal"> 2052<div id="tabs-3d7b80c486" class="cmp-tabs" data-cmp-is="tabs" data-placeholder-text="false"> 2053 <ol role="tablist" class="cmp-tabs__tablist" aria-multiselectable="false"> 2054 2055 <li role="tab" id="tabs-3d7b80c486-item-cb5f46eb92-tab" class="cmp-tabs__tab cmp-tabs__tab--active" aria-controls="tabs-3d7b80c486-item-cb5f46eb92-tabpanel" tabindex="0" data-cmp-hook-tabs="tab">VYVGART Hytrulo</li> 2056 2057 2058 <li role="tab" id="tabs-3d7b80c486-item-751b8bfe00-tab" class="cmp-tabs__tab" aria-controls="tabs-3d7b80c486-item-751b8bfe00-tabpanel" tabindex="-1" data-cmp-hook-tabs="tab">VYVGART</li> 2059 </ol> 2060 <div id="tabs-3d7b80c486-item-cb5f46eb92-tabpanel" role="tabpanel" aria-labelledby="tabs-3d7b80c486-item-cb5f46eb92-tab" tabindex="0" class="cmp-tabs__tabpanel cmp-tabs__tabpanel--active" data-cmp-hook-tabs="tabpanel" data-cmp-data-layer="{"tabs-3d7b80c486-item-cb5f46eb92":{"@type":"argenx/components/content/tabs/item","repo:modifyDate":"2026-05-27T18:20:51Z","dc:title":"VYVGART Hytrulo"}}"><div class="container responsivegrid"> 2061 2062 2063 <div id="container-5246432ba2" class="cmp-container"> 2064 2065 2066 2067<div class="aem-Grid aem-Grid--12 aem-Grid--small--12 aem-Grid--default--12 "> 2068 2069 <div class="text vyv-text--isi vyvgarthcp-text--p-margin-bottom-xs vyv-spacing--bottom-sm-4 vyvgarthcp-spacing--desktop-bottom--none aem-GridColumn--small--none aem-GridColumn aem-GridColumn--small--12 aem-GridColumn--offset--small--0 aem-GridColumn--default--12"> 2070<div id="text-d07c5ad4bf" class="cmp-text"> 2071 <h4 class="br-none-mobile"><b>IMPORTANT SAFETY INFORMATION AND INDICATION</b></h4> 2072<h4 class="br-none-mobile"><b>CONTRAINDICATIONS</b></h4> 2073<p>VYVGART HYTRULO is contraindicated in patients with serious hypersensitivity to efgartigimod alfa products, to hyaluronidase, or to any of the excipients of VYVGART HYTRULO. Reactions have included anaphylaxis and hypotension leading to syncope. </p> 2074<h4><b>WARNINGS AND PRECAUTIONS<br /> 2075</b> <b>Infections</b></h4> 2076<p>VYVGART HYTRULO may increase the risk of infection. The most common infections observed in Study 1 were urinary tract infection (10% of efgartigimod alfa-fcab-treated patients vs 5% of placebo-treated patients) and respiratory tract infections (33% of efgartigimod alfa-fcab-treated patients vs 29% of placebo-treated patients). Patients on efgartigimod alfa-fcab vs placebo had below normal levels for white blood cell counts (12% vs 5%, respectively), lymphocyte counts (28% vs 19%, respectively), and neutrophil counts (13% vs 6%, respectively). The majority of infections and hematologic abnormalities were mild to moderate in severity. Delay VYVGART HYTRULO administration in patients with an active infection until the infection has resolved; monitor for clinical signs and symptoms of infections. If serious infection occurs, administer appropriate treatment and consider withholding VYVGART HYTRULO until the infection has resolved.</p> 2077<h4><b>Immunization</b></h4> 2078<p>Evaluate the need to administer age-appropriate vaccines according to immunization guidelines before initiation of a new treatment cycle with VYVGART HYTRULO. The safety of immunization with live vaccines and the immune response to vaccination during treatment with VYVGART HYTRULO are unknown. Because VYVGART HYTRULO causes a reduction in immunoglobulin G (IgG) levels, vaccination with live vaccines is not recommended during treatment with VYVGART HYTRULO.</p> 2079<h4><b>Hypersensitivity Reactions</b></h4> 2080<p>In clinical trials, hypersensitivity reactions, including rash, angioedema, and dyspnea were observed in patients treated with VYVGART HYTRULO or intravenous efgartigimod alfa-fcab. Urticaria was also observed in patients treated with VYVGART HYTRULO. Hypersensitivity reactions were mild or moderate, occurred within 1 hour to 3 weeks of administration. Anaphylaxis and hypotension leading to syncope have been reported in postmarketing experience with intravenous efgartigimod alfa-fcab. Anaphylaxis and hypotension occurred during or within an hour of administration and led to infusion discontinuation and in some cases to permanent treatment discontinuation. Monitor for clinical signs and symptoms of hypersensitivity reactions for at least 30 minutes after administration. If a hypersensitivity reaction occurs, the healthcare professional should institute appropriate measures if needed or the patient should seek medical attention.</p> 2081<h4><b>Infusion/Injection-Related Reactions </b></h4> 2082<p>Infusion-related reactions have been reported with intravenous efgartigimod alfa-fcab in postmarketing experience. The most frequent symptoms and signs were hypertension, chills, shivering, and thoracic, abdominal, and back pain. Infusion-related reactions occurred during or within an hour of administration and led to infusion discontinuation. If a severe infusion/injection-related reaction occurs, initiate appropriate therapy. Consider the risks and benefits of readministering VYVGART HYTRULO following a severe infusion/injection-related reaction. If a mild to moderate infusion/injection-related reaction occurs, patients may be rechallenged with close clinical observation, slower infusion/injection rates, and pre-medications.</p> 2083<h4><b>ADVERSE REACTIONS</b></h4> 2084<p>Patients with gMG: In Study 1, the most common (â¥10%) adverse reactions in efgartigimod alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. In Study 2, the overall safety profile was consistent with the known safety profile of efgartigimod alfa-fcab in patients with gMG, except for nausea, which occurred in 7% of anti-acetylcholine receptor (AChR) antibody negative patients who received efgartigimod alfa-fcab compared to 5% of patients who received placebo. In Study 3, the most common (â¥10%) adverse reactions in VYVGART HYTRULO- treated patients were injection site reactions and headache. Injection site reactions occurred in 38% of VYVGART HYTRULO-treated patients, including injection site rash, erythema, pruritus, bruising, pain, and urticaria. In Study 3 and its open-label extension, all injection site reactions were mild to moderate in severity and did not lead to treatment discontinuation. The majority occurred within 24 hours after administration and resolved spontaneously. Most injection site reactions occurred during the first treatment cycle, and the incidence decreased with each subsequent cycle.<br /> 2085<br /> 2086Patients with CIDP: In Study 4 stage B, the overall safety profile observed in patients with CIDP treated with VYVGART HYTRULO was consistent with the known safety profile of VYVGART HYTRULO and of efgartigimod alfa-fcab administered intravenously. In Study 4, injection site reactions occurred in 15% of patients treated with VYVGART HYTRULO compared to 6% of patients who received placebo. The most common of these injection site reactions were injection site bruising and injection site erythema. All injection site reactions were mild to moderate in severity. Most injection site reactions occurred during the first 3 months of treatment.</p> 2087<h4><b>USE IN SPECIFIC POPULATIONS<br /> 2088 Pregnancy<br /> 2089 </b><span style=" font-weight: 400; 2090">As VYVGART HYTRULO is expected to reduce maternal IgG antibody levels, reduction in passive protection to the newborn is anticipated. Risk and benefits should be considered prior to administering live vaccines to infants exposed to VYVGART HYTRULO in utero.</span></h4> 2091<h4> </h4> 2092<h4><b>Lactation<br /> 2093 </b><span style=" font-weight: 400; 2094">There is no information regarding the presence of efgartigimod alfa or hyaluronidase, from administration of VYVGART HYTRULO, in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the motherâs clinical need for VYVGART HYTRULO and any potential adverse effects on the breastfed infant from VYVGART HYTRULO or from the underlying maternal
2094condition.</span></h4> 2095<h4> </h4> 2096 2097</div> 2098 2099 2100 2101</div> 2102<div class="text vyv-text--isi vyvgarthcp-text--p-margin-bottom-xs aem-GridColumn aem-GridColumn--default--12"> 2103<div id="text-ddeff36315" class="cmp-text"> 2104 <h4><b>INDICATION<br /> 2105 </b><span style=" font-weight: 400; 2106">VYVGART HYTRULO® (efgartigimod alfa and hyaluronidase-qvfc) is indicated for the treatment of adult patients with:</span></h4> 2107<ul><li style=" text-align: left; 2108">generalized myasthenia gravis (gMG)</li><li style=" text-align: left; 2109">chronic inflammatory demyelinating polyneuropathy (CIDP)</li></ul> 2110<p> </p> 2111<p><b style="">Please see the full <a href="https://www.argenx.com/product/vyvgart-hytrulo-prescribing-information.pdf" target="_blank" rel="noopener noreferrer">Prescribing Information</a>.</b></p> 2112<p>You may report side effects to the US Food and Drug Administration by visiting <a href="https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program">http://www.fda.gov/medwatch</a> or calling 1-800-FDA-1088. You may also report side effects to argenx US, Inc, at 1-833-argx411 (1-833-274-9411).</p> 2113<p><b>Dosage Forms and Strengths:</b> VYVGART Hytrulo is available as a single-dose subcutaneous injection containing: 200 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per prefilled syringe, or 180 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per vial.</p> 2114 2115</div> 2116 2117 2118 2119</div> 2120 2121 2122</div> 2123 2124 </div> 2125 2126 2127</div> 2128</div> 2129<div id="tabs-3d7b80c486-item-751b8bfe00-tabpanel" role="tabpanel" aria-labelledby="tabs-3d7b80c486-item-751b8bfe00-tab" tabindex="0" class="cmp-tabs__tabpanel" data-cmp-hook-tabs="tabpanel" data-cmp-data-layer="{"tabs-3d7b80c486-item-751b8bfe00":{"@type":"argenx/components/content/tabs/item","repo:modifyDate":"2026-05-27T18:20:51Z","dc:title":"VYVGART"}}"><div class="container responsivegrid"> 2130 2131 2132 <div id="container-ebbb56f5b3" class="cmp-container"> 2133 2134 2135 2136<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 "> 2137 2138 <div class="text vyv-text--isi vyvgarthcp-text--p-margin-bottom-xs vyv-spacing--bottom-sm-4 vyvgarthcp-spacing--desktop-bottom--none aem-GridColumn--default--none aem-GridColumn aem-GridColumn--default--12 aem-GridColumn--offset--default--0"> 2139<div id="text-f34f132268" class="cmp-text"> 2140 <h4 class="br-none-mobile"><b>IMPORTANT SAFETY INFORMATION AND INDICATION</b></h4> 2141<h4 class="br-none-mobile"><b>CONTRAINDICATIONS</b></h4> 2142<p>VYVGART is contraindicated in patients with serious hypersensitivity to efgartigimod alfa products or to any of the excipients of VYVGART. Reactions have included anaphylaxis and hypotension leading to syncope.</p> 2143<h4><b>WARNINGS AND PRECAUTIONS</b><br /> 2144<b>Infection</b></h4> 2145<p>VYVGART may increase the risk of infection. The most common infections observed in Study 1 were urinary tract infection (10% for VYVGART vs 5% for placebo) and respiratory tract infections (33% for VYVGART vs 29% for placebo). Patients on VYVGART vs placebo had below normal levels for white blood cell counts (12% vs 5%, respectively), lymphocyte counts (28% vs 19%, respectively), and neutrophil counts (13% vs 6%, respectively). The majority of infections and hematologic abnormalities were mild to moderate in severity. Delay VYVGART administration in patients with an active infection until the infection has resolved; monitor for clinical signs and symptoms of infections. If serious infection occurs, administer appropriate treatment and consider withholding VYVGART until the infection has resolved.</p> 2146<h4><b>Immunization</b></h4> 2147<p>Evaluate the need to administer age-appropriate vaccines according to immunization guidelines before initiation of a new treatment cycle with VYVGART. The safety of immunization with live vaccines and the immune response to vaccination during treatment with VYVGART are unknown. Because VYVGART causes a reduction in immunoglobulin G (IgG) levels, vaccination with live vaccines is not recommended during treatment with VYVGART.</p> 2148<h4><b>Hypersensitivity Reactions</b></h4> 2149<p>In clinical trials, hypersensitivity reactions, including rash, angioedema, and dyspnea were observed in VYVGART-treated patients. Hypersensitivity reactions were mild or moderate, occurred within 1 hour to 3 weeks of administration, and did not lead to treatment discontinuation. Anaphylaxis and hypotension leading to syncope have been reported in postmarketing experience with VYVGART. Anaphylaxis and hypotension occurred during or within an hour of administration and led to infusion discontinuation and in some cases to permanent treatment discontinuation. Monitor patients during administration and for 1 hour thereafter for clinical signs and symptoms of hypersensitivity reactions. If a hypersensitivity reaction occurs, the healthcare professional should institute appropriate measures if needed or the patient should seek medical attention.</p> 2150<h4><b>Infusion-Related Reactions</b></h4> 2151<p>Infusion-related reactions have been reported with VYVGART in postmarketing experience. The most frequent symptoms and signs were hypertension, chills, shivering, and thoracic, abdominal, and back pain. Infusion-related reactions occurred during or within an hour of administration and led to infusion discontinuation. If a severe infusion-related reaction occurs during administration, discontinue VYVGART infusion and initiate appropriate therapy. Consider the risks and benefits of readministering VYVGART following a severe infusion-related reaction. If a mild to moderate infusion-related reaction occurs, patients may be rechallenged with close clinical observation, slower infusion rates, and pre-medications.</p> 2152<h4><b>ADVERSE REACTIONS</b></h4> 2153<p>In Study 1, the most common (â¥10%) adverse reactions with VYVGART-treated patients were respiratory tract infection, headache, and urinary tract infection. In Study 2, the overall safety profile was consistent with the known safety profile of VYVGART in patients with gMG, except for nausea, which occurred in 7% of anti-acetylcholine receptor (AChR) antibody negative patients who received VYVGART compared to 5% of patients who received placebo.</p> 2154<h4><b>USE IN SPECIFIC POPULATIONS</b><br /> 2155<b>Pregnancy</b></h4> 2156<p>As VYVGART is expected to reduce maternal IgG antibody levels, reduction in passive protection to the newborn is anticipated. Risk and benefits should be considered prior to administering live vaccines to infants exposed to VYVGART in utero.</p> 2157<h4><b>Lactation</b></h4> 2158<p>There is no information regarding the presence of efgartigimod alfa-fcab in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the motherâs clinical need for VYVGART and any potential adverse effects on the breastfed infant from VYVGART or from the underlying maternal
2158condition.</p> 2159 2160</div> 2161 2162 2163 2164</div> 2165<div class="text vyv-text--isi aem-GridColumn aem-GridColumn--default--12"> 2166<div id="text-25ad042d61" class="cmp-text"> 2167 <h4 id="indication"><b>INDICATION</b></h4> 2168<p>VYVGART® (efgartigimod alfa-fcab) is indicated for the treatment of adult patients with generalized myasthenia gravis (gMG).</p> 2169<p><b>Please see the full <a href="https://www.argenx.com/product/vyvgart-prescribing-information.pdf">Prescribing Information</a>.</b></p> 2170<p>You may report side effects to the US Food and Drug Administration by visiting <a href="https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program">http://www.fda.gov/medwatch</a> or calling 1-800-FDA-1088. You may also report side effects to argenx US, Inc, at 1-833-argx411 (1-833-274-9411).</p> 2171<p><b>Dosage Form and Strength:</b> VYVGART is available as a single-dose injection for intravenous use containing 400 mg/20 mL of efgartigimod alfa-fcab per vial.</p> 2172 2173</div> 2174 2175 2176 2177</div> 2178 2179 2180</div> 2181 2182 </div> 2183 2184 2185</div> 2186</div> 2187 2188 2189</div> 2190</div> 2191 2192 2193 </div> 2194 2195</div> 2196 2197 2198 </div> 2199 2200</div> 2201 2202 2203</div> 2204 2205 </div> 2206 2207 2208</div> 2209 2210 2211 2212 2213 2214</div> 2215 2216 2217 </div> 2218 2219</div> 2220<div class="container responsivegrid"> 2221 2222 2223 2224 2225 <div id="container-6e8e7df58e" class="cmp-container"> 2226 2227 <div class="text vyvgarthcp-text--references"> 2228<div id="text-3c3289285f" class="cmp-text"> 2229 <p><b>References:</b> <b>1.</b> VYVGART. Prescribing information. argenx US Inc; 2026. <b>2.</b> VYVGART Hytrulo. Prescribing information. argenx US Inc; 2026.</p> 2230 2231</div> 2232 2233 2234 2235</div> 2236 2237 2238 </div> 2239 2240</div> 2241<footer class="container responsivegrid"> 2242 2243 2244 2245 2246 <div id="container-d72ada74a1" class="cmp-container"> 2247 2248 <div class="container responsivegrid"> 2249 2250 2251 2252 2253 <div id="container-48acb4d21d" class="cmp-container"> 2254 2255 2256 2257 </div> 2258 2259</div> 2260<div class="experiencefragment"> 2261<div id="experiencefragment-f5d4fdef32" class="cmp-experiencefragment cmp-experiencefragment--footer-links"> 2262 2263 2264 2265 <div id="container-16ceae92b7" class="cmp-container"> 2266 2267 2268 2269<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 "> 2270 2271 <div class="text vyvh-cidp-text--footer vyvgarthcp-text--medium aem-GridColumn aem-GridColumn--default--12"> 2272<div id="text-16870a934d" class="cmp-text"> 2273 <ul><li><a href="https://argenx.com/about" target="_blank" rel="noopener noreferrer">About argenx</a></li><li><a href="https://argenxmedical.com/" target="_blank" rel="noopener noreferrer">Medical Affairs</a></li><li><a href="https://www.argenx.com/contact-us" target="_blank" rel="noopener noreferrer">Contact us</a></li><li><a href="https://www.argenx.com/privacy-policy" target="_blank" rel="noopener noreferrer">Privacy Policy</a></li><li><a href="https://www.argenx.com/cookie-policy" target="_blank" rel="noopener noreferrer">Cookie Policy</a></li></ul> 2274 2275</div> 2276 2277 2278 2279</div> 2280 2281 2282</div> 2283 2284 </div> 2285 2286 2287</div> 2288 2289 2290</div> 2291<div class="container responsivegrid"> 2292 2293 2294 <div id="vyvgarthcp-main--footer" class="cmp-container"> 2295 2296 2297 2298<div class="aem-Grid aem-Grid--12 aem-Grid--small--12 aem-Grid--default--12 aem-Grid--xsmall--12 aem-Grid--phone--12 "> 2299 2300 <div class="container responsivegrid aem-GridColumn--small--none aem-GridColumn--default--none aem-GridColumn--phone--none aem-GridColumn--phone--12 aem-GridColumn aem-GridColumn--small--12 aem-GridColumn--offset--small--0 aem-GridColumn--offset--phone--0 aem-GridColumn--offset--default--0 aem-GridColumn--default--2"> 2301 2302 2303 2304 2305 <div id="container-f1ce373c3e" class="cmp-container"> 2306 2307 <div class="image"> 2308<div data-cmp-is="image" data-cmp-lazythreshold="0" data-cmp-src="/content/vyvgart/us/en/hcp/gmg/enroll-patients.coreimg{.width}.svg/structure/jcr:content/root/container_2013501416/container/container_copy/image_copy/1668012062403/argenx-logo-rgb.svg" data-asset="/content/dam/brand-portal/downloads/argenx/logos/rgb/argenx_logo_RGB.svg" data-asset-id="c15b310a-7b9f-4598-9b7b-29c6c5e6c937" data-title="argenx logo" id="footer-argenx-logo" class="cmp-image" itemscope itemtype="http://schema.org/ImageObject"> 2309 <a class="cmp-image__link" href="https://www.argenx.com/" data-cmp-hook-image="link"> 2310 2311 2312 <img src="/content/vyvgart/us/en/hcp/gmg/enroll-patients.coreimg.svg/stru
2312cture/_jcr_content/root/container_2013501416/container/container_copy/image_copy/1668012062403/argenx-logo-rgb.svg" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt="argenx logo"/> 2313 2314 2315 </a> 2316 2317 2318</div> 2319 2320 2321 2322</div> 2323 2324 2325 </div> 2326 2327</div> 2328<div class="container responsivegrid aem-GridColumn--small--none aem-GridColumn--offset--xsmall--0 aem-GridColumn--default--none aem-GridColumn--default--9 aem-GridColumn--xsmall--none aem-GridColumn aem-GridColumn--small--12 aem-GridColumn--offset--small--0 aem-GridColumn--xsmall--11 aem-GridColumn--offset--default--1"> 2329 2330 2331 2332 2333 <div id="container-2c60f4842c" class="cmp-container"> 2334 2335 <div class="text"> 2336<div id="text-1f17661c71" class="cmp-text"> 2337 <p>For US audiences only.<br /> 2338VYVGART and VYVGART Hytrulo are registered trademarks of argenx.<br /> 2339© 2026 argenx US-ESC-23-00055 V10 05/2026. All Rights Reserved.</p> 2340 2341</div> 2342 2343 2344 2345</div> 2346 2347 2348 </div> 2349 2350</div> 2351 2352 2353</div> 2354 2355 </div> 2356 2357 2358</div> 2359 2360 2361 </div> 2362 2363</footer> 2364<div class="overlay-modal"> 2365 <!-- Load vimeo player API --> 2366 2367 <div id="modal__contact-a-rep-thank-you" class="cmp-overlay-modal-pre__main-wrapper" data-modal-animation="none" aria-modal="true" role="dialog" aria-hidden='true'> 2368 <div class="cmp-overlay-modal-pre__main-backdrop"></div> 2369 <div class="cmp-overlay-modal-pre__main-modal"> 2370 <div class="cmp-overlay-modal-pre__main-modal-close-button" tabindex="0"> 2371 <span></span> 2372 <span></span> 2373 </div> 2374 <div class="cmp-overlay-modal-pre__main-modal-content"> 2375 2376 2377 2378 2379 2380 2381 <!-- Experience Fragment start --> 2382 <div id="overlay-modal-408ec76965" class="cmp-experiencefragment cmp-experiencefragment--contact-a-rep"> 2383 2384 2385 2386 <div id="container-0adec01ce0" class="cmp-container"> 2387 2388 2389 2390<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 "> 2391 2392 <div class="container responsivegrid vyvgarthcp-container--modal __contact-a-rep __close aem-GridColumn aem-GridColumn--default--12"> 2393 2394 2395 <div id="container-b619e614b2" class="cmp-container"> 2396 2397 2398 2399<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 "> 2400 2401 <div class="button aem-GridColumn aem-GridColumn--default--12"> 2402<button type="button" id="modal-x" class="cmp-button" target="_self"> 2403 2404 <span class="cmp-button__icon cmp-button__icon--modal-x" aria-hidden="true"></span> 2405 2406 <!--Added context for the button text--> 2407</button> 2408</div> 2409<div class="container responsivegrid aem-GridColumn aem-GridColumn--default--12"> 2410 2411 2412 <div id="wrapper" class="cmp-container"> 2413 2414 2415 2416<div class="aem-Grid aem-Grid--12 aem-Grid--small--12 aem-Grid--default--12 aem-Grid--xsmall--12 aem-Grid--medium--12 "> 2417 2418 <div class="container responsivegrid aem-GridColumn--offset--xsmall--0 aem-GridColumn--default--none aem-GridColumn--xsmall--12 aem-GridColumn--offset--default--0 aem-GridColumn--offset--medium--0 aem-GridColumn--small--hide aem-GridColumn--medium--12 aem-GridColumn aem-GridColumn--small--12 aem-GridColumn--offset--small--0 aem-GridColumn--default--4 aem-GridColumn--medium--hide aem-GridColumn--xsmall--hide"> 2419 2420 2421 2422 2423 <div id="container-ba17771e46" class="cmp-container"> 2424 2425 <div class="image"> 2426 2427 2428 2429 2430</div> 2431 2432 2433 </div> 2434 2435</div> 2436<div class="container responsivegrid aem-GridColumn--small--none aem-GridColumn--medium--none aem-GridColumn--offset--xsmall--0 aem-GridColumn--default--none aem-GridColumn--xsmall--12 aem-GridColumn--offset--default--0 aem-GridColumn--offset--medium--0 aem-GridColumn--xsmall--none aem-GridColumn--medium--12 aem-GridColumn aem-GridColumn--small--12 aem-GridColumn--offset--small--0 aem-GridColumn--default--8"> 2437 2438 2439 2440 2441 <div id="container-3c2ccd0cbf" class="cmp-container"> 2442 2443 <div class="text"> 2444<div id="text-61fc44831f" class="cmp-text"> 2445 <h6 class="vyvgarthcp-spacing--bottom-xsmall"><b>CONTACT A REP</b></h6> 2446<h3>Thank you! </h3> 2447<p>An argenx representative will reach out to you soon, so keep an eye on your inbox!</p> 2448 2449</div> 2450 2451 2452 2453</div> 2454 2455 2456 </div> 2457 2458</div> 2459 2460 2461</div> 2462 2463 </div> 2464 2465 2466</div> 2467 2468 2469</div> 2470 2471 </div> 2472 2473 2474</div> 2475 2476 2477</div> 2478 2479 </div> 2480 2481 2482</div> 2483 <!-- Video Section start --> 2484 2485 <!-- Video Section end --> 2486 2487 <!-- Content for the post video screen start --> 2488 2489 <!-- Content for the post video screen end --> 2490 </div> 2491 </div> 2492 </div> 2493 2494 2495 2496 2497</div> 2498<div class="overlay-modal"> 2499 <!-- Load vimeo player API --> 2500 2501 <div id="modal__hcp-confirmation" class="cmp-overlay-modal-pre__main-wrapper" aria-modal="true" role="dialog" aria-hidden='true'> 2502 <div class="cmp-overlay-modal-pre__main-backdrop"></div> 2503 <div class="cmp-overlay-modal-pre__main-modal"> 2504 <div class="cmp-overlay-modal-pre__main-modal-close-button" tabindex="0">
2505 <span></span> 2506 <span></span> 2507 </div> 2508 <div class="cmp-overlay-modal-pre__main-modal-content"> 2509 2510 2511 2512 2513 2514 2515 <!-- Experience Fragment start --> 2516 <div id="overlay-modal-929d4cd853" class="cmp-experiencefragment cmp-experiencefragment--hcp-confirmation"> 2517 2518 2519 2520 <div id="container-032a197f91" class="cmp-container"> 2521 2522 2523 2524<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 "> 2525 2526 <div class="container responsivegrid vyvgarthcp-container--modal __interstitial-hcp-confirmation cmp-external-site-popup-warning __close aem-GridColumn aem-GridColumn--default--12"> 2527 2528 2529 2530 2531 <div id="container-3d0e61aa82" class="cmp-container"> 2532 2533 <div class="image"> 2534<div data-cmp-is="image" data-cmp-lazythreshold="0" data-cmp-src="/content/experience-fragments/vyvgart/us/en/hcp/hcp-confirmation/master/_jcr_content/root/container_copy/image_copy_copy_copy.coreimg.90{.width}.png/1747103065110/co-branded-logos.png" data-cmp-widths="768,1200,1440,1980" data-asset="/content/dam/vyvgart/hcp/logos/co-branded-logos.png" data-title="co-branded logo" id="clickout-modal-logo" class="cmp-image" itemscope itemtype="http://schema.org/ImageObject"> 2535 2536 <noscript data-cmp-hook-image="noscript"> 2537 2538 <img src="/content/experience-fragments/vyvgart/us/en/hcp/hcp-confirmation/master/_jcr_content/root/container_copy/image_copy_copy_copy.coreimg.png/1747103065110/co-branded-logos.png" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt="co-branded logo"/> 2539 2540 </noscript> 2541 2542 2543 2544</div> 2545 2546 2547 2548</div> 2549<div class="text vyv-spacing--top-sm-4 vyv-spacing--bottom-sm-4"> 2550<div id="text-e2629a892a" class="cmp-text"> 2551 <h3>This information is intended for US<br /> 2552healthcare professionals only</h3> 2553 2554</div> 2555 2556 2557 2558</div> 2559<div class="button vyvgarthcp-button--secondary vyvgarthcp-button--rounded-r4"> 2560<a id="modal-x" class="cmp-button" href="#" target="_self"> 2561 2562 2563 2564 <span class="cmp-button__text">I am a US healthcare professional</span> <!--Added context for the button text--> 2565</a> 2566</div> 2567<div class="button vyv-button--ghost vyvgarthcp-button--rounded-r4"> 2568<a id="not-hcp" class="cmp-button" href="https://vyvgart.com/" target="_self"> 2569 2570 2571 2572 <span class="cmp-button__text">I am not a US healthcare professional </span> <!--Added context for the button text--> 2573</a> 2574</div> 2575 2576 2577 </div> 2578 2579</div> 2580 2581 2582</div> 2583 2584 </div> 2585 2586 2587</div> 2588 <!-- Video Section start --> 2589 2590 <!-- Video Section end --> 2591 2592 <!-- Content for the post video screen start --> 2593 2594 <!-- Content for the post video screen end --> 2595 </div> 2596 </div> 2597 </div> 2598 2599 2600 2601 2602</div> 2603<div class="overlay-modal"> 2604 <!-- Load vimeo player API --> 2605 2606 <div id="modal__search" class="cmp-overlay-modal-pre__main-wrapper" aria-modal="true" role="dialog" aria-hidden='true'> 2607 <div class="cmp-overlay-modal-pre__main-backdrop"></div> 2608 <div class="cmp-overlay-modal-pre__main-modal"> 2609 <div class="cmp-overlay-modal-pre__main-modal-close-button" tabindex="0"> 2610 <span></span> 2611 <span></span> 2612 </div> 2613 <div class="cmp-overlay-modal-pre__main-modal-content"> 2614 2615 2616 2617 2618 2619 2620 <!-- Experience Fragment start --> 2621 <div id="overlay-modal-ded45c8553" class="cmp-experiencefragment cmp-experiencefragment--search-modal"> 2622 2623 2624 2625 <div id="container-261eb48ebe" class="cmp-container"> 2626 2627 2628 2629<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 "> 2630 2631 <div class="container responsivegrid vyvgarthcp-container--modal __close aem-GridColumn aem-GridColumn--default--12"> 2632 2633 2634 <div id="search-modal" class="cmp-container"> 2635 2636 2637 2638<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 "> 2639 2640 <div class="button aem-GridColumn aem-GridColumn--default--12"> 2641<button type="button" id="modal-x" class="cmp-button" target="_self"> 2642 2643 <span class="cmp-button__icon cmp-button__icon--modal-x" aria-hidden="true"></span> 2644 2645 <!--Added context for the button text--> 2646</button> 2647</div> 2648<div class="text vyv-spacing--bottom-sm-7 vyvgarthcp-text--font-weight-sm aem-GridColumn aem-GridColumn--default--12"> 2649<div id="text-5e2103692e" class="cmp-text"> 2650 <h3 style=" text-align: center; 2651 margin-top: 0; 2652">Search for:</h3> 2653 2654</div> 2655 2656 2657 2658</div> 2659<div class="container responsivegrid aem-GridColumn aem-GridColumn--default--12"> 2660<form method="POST" action="/gmg/enroll-patients" id="new_form" name="new_form" enctype="multipart/form-data" class="cmp-form aem-Grid aem-Grid--12 aem-Grid--small--12 aem-Grid--default--12 aem-Grid--xsmall--12"> 2661 2662 <input type="hidden" name=":formstart" value="/content/experience-fragments/vyvgart/us/en/hcp/search-modal/master/jcr:content/root/container_
2662copy_copy_/container"/> 2663 <input type="hidden" name="_charset_" value="utf-8"/> 2664 2665 <div class="text aem-GridColumn aem-GridColumn--default--12"> 2666 <div class="cmp-form-text" data-cmp-is="formText"> 2667 2668 2669 2670 <input class="cmp-form-text__text" data-cmp-hook-form-text="input" aria-label="search" type="text" id="form-text-1923461428" name="search" value="enter search term"/> 2671</div></div> 2672<div class="button vyv-button--center-mobile aem-GridColumn--small--none aem-GridColumn--offset--xsmall--0 aem-GridColumn--xsmall--12 aem-GridColumn--xsmall--none aem-GridColumn aem-GridColumn--small--12 aem-GridColumn--offset--small--0 aem-GridColumn--default--12"> 2673<button type="BUTTON" id="form-button-1109831993" class="cmp-form-button">Search</button> 2674</div> 2675 2676 2677</form> 2678</div> 2679 2680 2681</div> 2682 2683 </div> 2684 2685 2686</div> 2687 2688 2689</div> 2690 2691 </div> 2692 2693 2694</div> 2695 <!-- Video Section start --> 2696 2697 <!-- Video Section end --> 2698 2699 <!-- Content for the post video screen start --> 2700 2701 <!-- Content for the post video screen end --> 2702 </div> 2703 </div> 2704 </div> 2705 2706 2707 2708 2709</div> 2710<div class="overlay-modal"> 2711 <!-- Load vimeo player API --> 2712 2713 <div id="modal__lightbox" class="cmp-overlay-modal-pre__main-wrapper" aria-modal="true" role="dialog" aria-hidden='true'> 2714 <div class="cmp-overlay-modal-pre__main-backdrop"></div> 2715 <div class="cmp-overlay-modal-pre__main-modal"> 2716 <div class="cmp-overlay-modal-pre__main-modal-close-button" tabindex="0"> 2717 <span></span> 2718 <span></span> 2719 </div> 2720 <div class="cmp-overlay-modal-pre__main-modal-content"> 2721 2722 2723 2724 2725 2726 2727 <!-- Experience Fragment start --> 2728 <div id="overlay-modal-3891c2416e" class="cmp-experiencefragment cmp-experiencefragment--lightbox-modal"> 2729 2730 2731 2732 <div id="container-03977db68a" class="cmp-container"> 2733 2734 2735 2736<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 "> 2737 2738 <div class="container responsivegrid vyvgarthcp-container--modal __close aem-GridColumn aem-GridColumn--default--12"> 2739 2740 2741 <div id="container-cb28261ca3" class="cmp-container"> 2742 2743 2744 2745<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 "> 2746 2747 <div class="button aem-GridColumn aem-GridColumn--default--12"> 2748<button type="button" id="modal-x" class="cmp-button" target="_self"> 2749 2750 <span class="cmp-button__icon cmp-button__icon--modal-x-white" aria-hidden="true"></span> 2751 2752 <!--Added context for the button text--> 2753</button> 2754</div> 2755 2756 2757</div> 2758 2759 </div> 2760 2761 2762</div> 2763 2764 2765</div> 2766 2767 </div> 2768 2769 2770</div> 2771 <!-- Video Section start --> 2772 2773 <!-- Video Section end --> 2774 2775 <!-- Content for the post video screen start --> 2776 2777 <!-- Content for the post video screen end --> 2778 </div> 2779 </div> 2780 </div> 2781 2782 2783 2784 2785</div> 2786<div class="overlay-modal"> 2787 <!-- Load vimeo player API --> 2788 2789 <div id="modal__videos" class="cmp-overlay-modal-pre__main-wrapper" aria-modal="true" role="dialog" aria-hidden='true'> 2790 <div class="cmp-overlay-modal-pre__main-backdrop"></div> 2791 <div class="cmp-overlay-modal-pre__main-modal"> 2792 <div class="cmp-overlay-modal-pre__main-modal-close-button" tabindex="0"> 2793 <span></span> 2794 <span></span> 2795 </div> 2796 <div class="cmp-overlay-modal-pre__main-modal-content"> 2797 2798 2799 2800 2801 2802 2803 <!-- Experience Fragment start --> 2804 <div id="overlay-modal-7fb91286f5" class="cmp-experiencefragment cmp-experiencefragment--video-playlist-modal"> 2805 2806 2807 2808 <div id="container-24fb0ced66" class="cmp-container"> 2809 2810 2811 2812<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 "> 2813 2814 <div class="container responsivegrid vyvgarthcp-container--modal __video-playlist __close aem-GridColumn aem-GridColumn--default--12"> 2815 2816 2817 2818 2819 <div id="container-ed233e20fb" class="cmp-container"> 2820 2821 <div class="button"> 2822<button type="button" id="modal-x" class="cmp-button" target="_self"> 2823 2824 <span class="cmp-button__icon cmp-button__icon--modal-x-white" aria-hidden="true"></span> 2825 2826 <!--Added context for the button text--> 2827</button> 2828</div> 2829<div class="video-playlist">
2829 <div class="cmp-video"> 2830 <section class="cmp-video__main"> 2831 <div class="cmp-video__player-container"> 2832 <div class="cmp-video__section-wrapper"> 2833 <div class="cmp-video__section-block"> 2834 <h2>Video Playlist</h2> 2835 <h3 class="cmp-video__text"> 2836 2837 </h3> 2838 </div> 2839 </div> 2840 2841 <div class="cmp-video__player" data-vimeo-url="https://player.vimeo.com/video/"> 2842 <iframe width="640" height="361" frameborder="0" allow="autoplay; fullscreen"></iframe> 2843 </div> 2844 2845 2846 <div id="demo" class="carousel slide" data-ride="carousel"> 2847 <!-- Indicators --> 2848 <ul class="carousel-indicators"> 2849 <li data-target="#demo" data-slide-to="0" class="active"></li> 2850 <li data-target="#demo" data-slide-to="1"></li> 2851 <li data-target="#demo" data-slide-to="2"></li> 2852 </ul> 2853 2854 <!-- The slideshow --> 2855 2856 2857 <!-- Left and right controls --> 2858 <a class="carousel-control-prev" href="#demo" data-slide="prev"> 2859 <span class="carousel-control-prev-icon"></span> 2860 </a> 2861 <a class="carousel-control-next" href="#demo" data-slide="next"> 2862 <span class="carousel-control-next-icon"></span> 2863 </a> 2864 2865</div> 2866 2867 </div> 2868 </section> 2869</div> 2870 2871 2872 2873</div> 2874<div class="container responsivegrid"> 2875 2876 2877 2878 2879 <div id="isi-container" class="cmp-container"> 2880 2881 <div class="text"> 2882<div id="text-510f99ae2e" class="cmp-text"> 2883 <h4>IMPORTANT SAFETY INFORMATION AND INDICATION<br /> 2884CONTRAINDICATIONS</h4> 2885<p>VYVGART and VYVGART HYTRULO are contraindicated in patients with serious hypersensitivity to efgartigimod alfa products or to any of the excipients of VYVGART or VYVGART HYTRULO, respectively. VYVGART HYTRULO is also contraindicated in patients with serious hypersensitivity to hyaluronidase. Reactions have included anaphylaxis and hypotension leading to syncope.</p> 2886<h4>WARNINGS AND PRECAUTIONS<br /> 2887Infections</h4> 2888<p>VYVGART and VYVGART HYTRULO may increase the risk of infection. The most common infections observed in Study 1 were urinary tract infection (10% of efgartigimod alfa-fcab-treated patients vs 5% of placebo-treated patients) and respiratory tract infection (33% of efgartigimod alfa-fcab-treated patients vs 29% of placebo-treated patients). Patients on efgartigimod alfa-fcab vs placebo had below normal levels for white blood cell counts (12% vs 5%, respectively), lymphocyte counts (28% vs 19%, respectively), and neutrophil counts (13% vs 6%, respectively). The majority of infections and hematologic abnormalities were mild to moderate in severity. Delay the administration of VYVGART or VYVGART HYTRULO in patients with an active infection until the infection has resolved; monitor for clinical signs and symptoms of infections. If serious infection occurs, administer appropriate treatment and consider withholding treatment with VYVGART or VYVGART HYTRULO until the infection has resolved.</p> 2889<h4>Immunization</h4> 2890<p>Evaluate the need to administer age-appropriate vaccines according to immunization guidelines before initiation of a new treatment cycle with VYVGART or VYVGART HYTRULO. The safety of immunization with live vaccines and the immune response to vaccination during treatment with VYVGART or VYVGART HYTRULO are unknown. Because VYVGART and VYVGART HYTRULO cause a reduction in immunoglobulin G (IgG) levels, vaccination with live vaccines is not recommended during treatment with VYVGART or VYVGART HYTRULO.</p> 2891<h4>Hypersensitivity Reactions</h4> 2892<p>In clinical trials, hypersensitivity reactions, including rash, angioedema, and dyspnea were observed in patients treated with VYVGART or VYVGART HYTRULO. Urticaria was also observed in patients treated with VYVGART HYTRULO. Hypersensitivity reactions were mild or moderate, occurred within 1 hour to 3 weeks of administration. Anaphylaxis and hypotension leading to syncope have been reported in postmarketing experience with intravenous efgartigimod alfa-fcab. Anaphylaxis and hypotension occurred during or within an hour of administration and led to infusion discontinuation and in some cases to permanent treatment discontinuation. Monitor for clinical signs and symptoms of hypersensitivity reactions during and for 1 hour after VYVGART administration, or for at least 30 minutes after VYVGART HYTRULO administration. If a hypersensitivity reaction occurs, the healthcare professional should institute appropriate measures if needed or the patient should seek medical attention.</p> 2893<h4>Infusion-Related Reactions</h4> 2894<p>Infusion-related reactions have been reported with VYVGART in postmarketing experience. The most frequent symptoms and signs were hypertension, chills, shivering, and thoracic, abdominal, and back pain. Infusion-related reactions occurred during or within an hour of administration and led to infusion discontinuation. If a severe infusion-related reaction occurs during administration, discontinue VYVGART infusion and initiate appropriate therapy. Consider the risks and benefits of readministering VYVGART following a severe infusion-related reaction. If a mild to moderate infusion-related reaction occurs, patients may be rechallenged with close clinical observation, slower infusion rates, and pre-medications.</p> 2895<h4>Infusion/Injection-Related Reactions</h4> 2896<p>Infusion-related reactions have been reported with intravenous efgartigimod alfa-fcab in postmarketing experience. The most frequent symptoms and signs were hypertension, chills, shivering, and thoracic, abdominal, and back pain. Infusion-related reactions occurred during or within an hour of administration and led to infusion discontinuation. If a severe infusion/injection-related reaction occurs, initiate appropriate therapy. Consider the risks and benefits of readministering VYVGART HYTRULO following a severe infusion/injection-related reaction. If a mild to moderate infusion/injection-related reaction occurs, patients may be rechallenged with close clinical observation, slower infusion/injection rates, and pre-medications.</p> 2897<h4>ADVERSE REACTIONS</h4> 2898<p>In Study 1, the most common (â¥10%) adverse reactions in efgartigimod alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. In Study 2, the most common (â¥10%) adverse reactions in VYVGART HYTRULO-treated patients were injection site reactions and headache. Injection site reactions occurred in 38% of VYVGART HYTRULO-treated patients, including injection site rash, erythema, pruritus, bruising, pain, and urticaria. In Study 2 and its open-label extension, all injection site reactions were mild to moderate in severity and did not lead to treatment discontinuation. The majority occurred within 24 hours after administration and resolved spontaneously. Most injection site reactions occurred during the first treatment cycle, and the incidence decreased with each subsequent cycle.</p> 2899<h4>USE IN SPECIFIC POPULATIONS<br /> 2900Pregnancy</h4> 2901<p>As VYVGART and VYVGART HYTRULO are expected to reduce maternal IgG antibody levels, reduction in passive protection to the newborn is anticipated. Risk and benefits should be considered prior to administering live vaccines to infants exposed to VYVGART or VYVGART HYTRULO in utero.</p> 2902<h4>Lactation</h4> 2903<p>There is no information regarding the presence of efgartigimod alfa-fcab from administration of VYVGART, or efgartigimod alfa or hyaluronidase from administration of VYVGART HYTRULO, in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the motherâs clinical need for VYVGART or VYVGART HYTRULO, and any potential adverse effects on the breastfed infant from VYVGART or VYVGART HYTRULO or from the underlying maternal
2903condition.</p> 2904<h4>INDICATION</h4> 2905<p>VYVGART® (efgartigimod alfa-fcab) for intravenous infusion and VYVGART HYTRULO® (efgartigimod alfa and hyaluronidase-qvfc) for subcutaneous injection are each indicated for the treatment of generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.<br /> 2906<br /> 2907Please see the full <a href="https://argenx.com/content/dam/argenx-corp/products/vyvgart-prescribing-information.pdf">Prescribing Information</a> for VYVGART and the full <a href="https://argenx.com/content/dam/argenx-corp/products/vyvgart-hytrulo-prescribing-information.pdf">Prescribing Information</a> for VYVGART HYTRULO.</p> 2908<p>You may report side effects to the US Food and Drug Administration by visiting <a href="https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program">http://www.fda.gov/medwatch</a> or calling 1-800-FDA-1088. You may also report side effects to argenx US, Inc, at 1-833-argx411 (1-833-274-9411).</p> 2909<p><b>Dosage Forms and Strengths:</b> VYVGART Hytrulo is available as a single-dose subcutaneous injection containing 180 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per vial.</p> 2910<p>VYVGART is available as a single-dose injection for intravenous use containing 400 mg/20 mL of efgartigimod alfa-fcab per vial.</p> 2911 2912</div> 2913 2914 2915 2916</div> 2917 2918 2919 </div> 2920 2921</div> 2922 2923 2924 </div> 2925 2926</div> 2927 2928 2929</div> 2930 2931 </div> 2932 2933 2934</div> 2935 <!-- Video Section start --> 2936 2937 <!-- Video Section end --> 2938 2939 <!-- Content for the post video screen start --> 2940 2941 <!-- Content for the post video screen end --> 2942 </div> 2943 </div> 2944 </div> 2945 2946 2947 2948 2949</div> 2950<div class="overlay-modal"> 2951 <!-- Load vimeo player API --> 2952 2953 <div id="modal__contact-a-rep" class="cmp-overlay-modal-pre__main-wrapper" data-modal-animation="none" aria-modal="true" role="dialog" aria-hidden='true'> 2954 <div class="cmp-overlay-modal-pre__main-backdrop"></div> 2955 <div class="cmp-overlay-modal-pre__main-modal"> 2956 <div class="cmp-overlay-modal-pre__main-modal-close-button" tabindex="0"> 2957 <span></span> 2958 <span></span> 2959 </div> 2960 <div class="cmp-overlay-modal-pre__main-modal-content"> 2961 2962 2963 2964 2965 2966 2967 <!-- Experience Fragment start --> 2968 <div id="overlay-modal-c423fb9e92" class="cmp-experiencefragment cmp-experiencefragment--contact-a-rep"> 2969 2970 2971 2972 <div id="container-40d8671bb5" class="cmp-container"> 2973 2974 2975 2976<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 "> 2977 2978 <div class="container responsivegrid vyvgarthcp-container--modal __contact-a-rep-cidp __close aem-GridColumn aem-GridColumn--default--12"> 2979 2980 2981 <div id="container-8e2d797790" class="cmp-container"> 2982 2983 2984 2985<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 "> 2986 2987 <div class="button aem-GridColumn aem-GridColumn--default--12"> 2988<button type="button" id="modal-x" class="cmp-button" target="_self"> 2989 2990 <span class="cmp-button__icon cmp-button__icon--modal-x" aria-hidden="true"></span> 2991 2992 <!--Added context for the button text--> 2993</button> 2994</div> 2995<div class="contact-a-rep contact-a-rep-modal gmg-modal aem-GridColumn aem-GridColumn--default--12"><div class="contact-a-rep--gmg modal-overlay" id="gmg"> 2996 <div class="modal"> 2997 <form id="contact-rep-form" data-endpoint-url="/content/vyvgart/us/en/hcp/jcr:content.contact-a-rep.html" data-formtype="gmg"> 2998 <div class="modal-wrapper"> 2999 3000 3001 3002 3003 3004<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 "> 3005 3006 <div class="container responsivegrid vyv-spacing--bottom-sm-7 aem-GridColumn aem-GridColumn--default--12"> 3007 3008 3009 3010 3011 <div id="container-9d0b8035f2" class="cmp-container"> 3012 3013 <div class="text vyvh-cidp-text--section-label perfectly-violet"> 3014<div id="text-9ce923dd21" class="cmp-text"> 3015 <p style=" text-align: center; 3016">For US healthcare professionals only</p> 3017 3018</div> 3019 3020 3021 3022</div> 3023<div class="text vyvgarthcp-color--perfectly-violet vyv-spacing--top-sm-7"> 3024<div id="text-06f7b734a2" class="cmp-text"> 3025 <p style=" text-align: center; 3026"><b>If you are a patient, please <a href="https://www.vyvgart.com/">click here</a>
3026 or call the VYVGART gMG â¨Education Line (inbound number: 1-833-VYVGART [1-833-898-4278])</b></p> 3027 3028</div> 3029 3030 3031 3032</div> 3033<div class="separator"> 3034<div id="separator-18e718535a" class="cmp-separator"> 3035 <hr class="cmp-separator__horizontal-rule"/> 3036</div></div> 3037 3038 3039 </div> 3040 3041</div> 3042<div class="text vyvgarthcp-color--perfectly-violet vyv-spacing--bottom-sm-4 aem-GridColumn aem-GridColumn--default--12"> 3043<div id="text-37deb47f3a" class="cmp-text"> 3044 <h6 style=" text-align: center; 3045"><b>CONTACT A REP</b></h6> 3046 3047</div> 3048 3049 3050 3051</div> 3052<div class="text vyv-spacing--bottom-sm-10 aem-GridColumn aem-GridColumn--default--12"> 3053<div id="text-e105141a06" class="cmp-text"> 3054 <h2 style=" text-align: center; 3055">Our argenx representatives can give healthcare professionals and office staff more information about <b>treatment for gMG</b></h2> 3056 3057</div> 3058 3059 3060 3061</div> 3062<div class="container responsivegrid vyv-spacing--bottom-sm-4 vyvgarthcp-spacing--mobile-bottom--none flex _fill flex-gap-xs _reset-mobile input-row three-input-row aem-GridColumn aem-GridColumn--default--12"> 3063 3064 3065 3066 3067 <div id="container-1b5dc050af" class="cmp-container"> 3068 3069 <div class="text"> 3070 <div class="cmp-form-text" data-cmp-is="formText" data-cmp-constraint-message="all fields are required"> 3071 3072 3073 3074 <input class="cmp-form-text__text" data-cmp-hook-form-text="input" aria-label="First Name" type="text" id="first-name" placeholder="First name" name="firstName" required aria-describedby="first-name-helpMessage"/> 3075</div></div> 3076<div class="text"> 3077 <div class="cmp-form-text" data-cmp-is="formText"> 3078 3079 3080 3081 <input class="cmp-form-text__text" data-cmp-hook-form-text="input" aria-label="Last Name" type="text" id="last-name" placeholder="Last name" name="lastName" required aria-describedby="last-name-helpMessage"/> 3082</div></div> 3083<div class="text"> 3084 <div class="cmp-form-text" data-cmp-is="formText"> 3085 3086 3087 3088 <input class="cmp-form-text__text" data-cmp-hook-form-text="input" aria-label="ZIP Code" type="text" id="zip-code" placeholder="ZIP code" name="postalCode" required aria-describedby="zip-code-helpMessage"/> 3089</div></div> 3090 3091 3092 </div> 3093 3094</div> 3095<div class="container responsivegrid vyv-spacing--bottom-sm-4 vyvgarthcp-spacing--mobile-bottom--none flex _fill flex-gap-xs _reset-mobile aem-GridColumn aem-GridColumn--default--12"> 3096 3097 3098 3099 3100 <div id="container-bdc5ed194f" class="cmp-container"> 3101 3102 <div class="text"> 3103 <div class="cmp-form-text" data-cmp-is="formText"> 3104 3105 3106 3107 <input class="cmp-form-text__text" data-cmp-hook-form-text="input" aria-label="Email" type="text" id="email" placeholder="Email address" name="email" required aria-describedby="email-helpMessage"/> 3108</div></div> 3109<div class="text"> 3110 <div class="cmp-form-text" data-cmp-is="formText"> 3111 3112 3113 3114 <input class="cmp-form-text__text" data-cmp-hook-form-text="input" aria-label="Phone Number" type="text" id="phoneNumber" placeholder="Phone number (optional)" name="mobilePhone" aria-describedby="phoneNumber-helpMessage"/> 3115</div></div> 3116 3117 3118 </div> 3119 3120</div> 3121<div class="container responsivegrid vyv-spacing--bottom-sm-4 vyvgarthcp-spacing--mobile-bottom--none flex _fill flex-gap-xs _reset-mobile input-row aem-GridColumn aem-GridColumn--default--12"> 3122 3123 3124 3125 3126 <div id="container-1262bd596c" class="cmp-container"> 3127 3128 <div class="options _flex _reset-flex-mobile"> 3129 3130 3131 <fieldset class="cmp-form-options cmp-form-options--drop-down" id="form-options-1856017657"> 3132 3133 3134 <label class="cmp-form-options__label" for="form-options-1856017657"> What is your role in the treatment journey?</label> 3135 <select class="cmp-form-options__field cmp-form-options__field--drop-down" required="true" name="treatmentJourneyRole" id="form-options-1856017657"> 3136 3137 3138 <option value="...">Select...</option> 3139 3140 <option value="Neurologist">Neurologist</option> 3141 3142 <option value="Neuromuscular specialist">Neuromuscular specialist</option> 3143 3144 <option value="Neuro-ophthalmologist">Neuro-ophthalmologist</option> 3145 3146 <option value="Physician">Physician</option> 3147 3148 <option value="Physician assistant (PA)">Physician assistant (PA)</option> 3149 3150 <option value="Nurse practitioner (NP)">Nurse practitioner (NP)</option> 3151 3152 <option value="Nurse">Nurse</option> 3153 3154 <option value="Medical staff">Medical staff</option> 3155 3156 <option value="Office staff">Office staff</option> 3157 3158 <option value="Infusion center staff">Infusion center staff</option> 3159 3160 <option value="Resident / Fellow">Resident / Fellow</option> 3161 3162 <option value="Pharmacist">Pharmacist</option> 3163 3164 <option value="Other">Other</option> 3165 3166 </select> 3167 3168 3169 </fieldset> 3170 3171 3172 3173</div> 3174 3175 3176 </div> 3177 3178</div> 3179<div class="container responsivegrid aem-GridColumn aem-GridColumn--default--12"> 3180 3181 3182 3183 3184 <div id="container-f76cb7b9c2" class="cmp-container"> 3185 3186 <div class="hidden field-optional"> 3187<input type="hidden" id="privacy-policy" name="Privacy Policy.*" value="https://www.argenx.com/privacy-policy"/> 3188 3189 3190</div> 3191 3192 3193 </div> 3194 3195</div> 3196<div class="text vyvgarthcp-text--small vyv-spacing--bottom-sm-4 vyvgarthcp-text--p-margin-bottom-xs vyv-spacing--top-sm-4 modal__body--content aem-GridColumn aem-GridColumn--default--12"> 3197<div id="text-e8b3f7860c" class="cmp-text"> 3198 <p style=" text-align: center; 3199">I authorize argenx to contact me for marketing purposes, such as to provide me with information, offers and promotions regarding argenx therapeutic areas, products, and programs, to conduct market research or surveys, and to use my Information to develop future products, services and programs. I understand that I may withdraw my authorization provided above by emailing <a href="mailto:privacy@argenx.com">privacy@argenx.com</a> or following the unsubscribe instructions on the communication. Unless I withdraw this authorization, it will remain effective for 5 years. Copies of this authorization may be obtained by emailing <a href="mailto:privacy@argenx.com">privacy@argenx.com</a>.</p> 3200<p style=" text-align: center; 3201">By clicking âI Agree,â I agree to the terms and conditions shown above and certify that I am 18 years of age or older. I understand that argenxâs Privacy Policy can be found at this <a href="https://argenx.com/privacy-policy" target="_blank" rel="noopener noreferrer">link</a>.</p> 3202 3203</div> 3204 3205 3206 3207</div> 3208<div class="button modal__body--btn _center aem-GridColumn aem-GridColumn--default--12"> 3209<button type="BUTTON" id="submit-form" class="cmp-form-button" name="submit-form">I agree</button> 3210</div> 3211<div class="hidden aem-GridColumn aem-GridColumn--default--12"> 3212<input type="hidden" id="form-hidden-1777517390" name="country" value="US"/> 3213 3214 3215</div> 3216<div class="hidden aem-GridColumn aem-GridColumn--default--12"> 3217<input type="hidden" id="form-hidden-1198810345" name="region" value="US"/> 3218 3219 3220</div> 3221<div class="hidden aem-GridColumn aem-GridColumn--default--12"> 3222<input type="hidden" id="form-hidden-1973383868" name="partitionName" value="US"/> 3223 3224 3225</div> 3226 3227 3228</div> 3229 3230 3231 <input type="hidden" class="formType" name="formType" value="gmg"/> 3232 3233 3234 3235 </div> 3236 <button id="closeModal">
3237 <span class="modal__close--icon"></span> 3238 </button> 3239 <div class="modal__header thankyou-modal" id="thankyou-modal"> 3240 <div class="modal__header--pretitle"> 3241 <h6>CONTACT A REP</h6> 3242 </div> 3243 <div class="modal__header--title"> 3244 <h3 id="thankyou">Thank You!</h3> 3245 </div> 3246 <div class="modal__header--content"> 3247 <p>An argenx representative will reach out to you soon, so keep an eye on your inbox!</p> 3248 </div> 3249 </div> 3250 </form> 3251 </div> 3252</div></div> 3253 3254 3255</div> 3256 3257 </div> 3258 3259 3260</div> 3261 3262 3263</div> 3264 3265 </div> 3266 3267 3268</div> 3269 <!-- Video Section start --> 3270 3271 <!-- Video Section end --> 3272 3273 <!-- Content for the post video screen start --> 3274 3275 <!-- Content for the post video screen end --> 3276 </div> 3277 </div> 3278 </div> 3279 3280 3281 3282 3283</div> 3284<div class="overlay-modal"> 3285 <!-- Load vimeo player API --> 3286 3287 <div id="modal__gmg-now-approved-all-serotypes" class="cmp-overlay-modal-pre__main-wrapper" aria-modal="true" role="dialog" aria-hidden='true'> 3288 <div class="cmp-overlay-modal-pre__main-backdrop"></div> 3289 <div class="cmp-overlay-modal-pre__main-modal"> 3290 <div class="cmp-overlay-modal-pre__main-modal-close-button" tabindex="0"> 3291 <span></span> 3292 <span></span> 3293 </div> 3294 <div class="cmp-overlay-modal-pre__main-modal-content"> 3295 3296 3297 3298 3299 3300 3301 <!-- Experience Fragment start --> 3302 <div id="overlay-modal-9493dd16af" class="cmp-experiencefragment cmp-experiencefragment--now-approved-all-serotypes-popup"> 3303 3304 3305 3306 <div id="container-024fa8308d" class="cmp-container"> 3307 3308 3309 3310<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 "> 3311 3312 <div class="container responsivegrid vyvgarthcp-container--modal vyv-now-approved-all-serotypes__popup __close aem-GridColumn aem-GridColumn--default--12"> 3313 3314 3315 <div id="container-3a959d7ad8" class="cmp-container"> 3316 3317 3318 3319<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 "> 3320 3321 <div class="image aem-GridColumn aem-GridColumn--default--12"> 3322<div data-cmp-is="image" data-cmp-lazythreshold="0" data-cmp-src="/content/experience-fragments/vyvgart/us/en/hcp/now-approved-all-serotypes-popup/master/_jcr_content/root/container_copy_copy_/image.coreimg.90{.width}.png/1778078671070/now-approved-all-serotypes-co-branded-logos.png" data-cmp-widths="768,1200,1440,1980" data-asset="/content/dam/vyvgart/hcp/now-approved-all-serotypes-co-branded-logos.png" data-title="VYVGART Hytrulo and VYVGART" id="now-approved-all-serotypes-logo" class="cmp-image" itemscope itemtype="http://schema.org/ImageObject"> 3323 3324 <noscript data-cmp-hook-image="noscript"> 3325 3326 <img src="/content/experience-fragments/vyvgart/us/en/hcp/now-approved-all-serotypes-popup/master/_jcr_content/root/container_copy_copy_/image.coreimg.png/1778078671070/now-approved-all-serotypes-co-branded-logos.png" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt="VYVGART Hytrulo and VYVGART"/> 3327 3328 </noscript> 3329 3330 3331 3332</div> 3333 3334 3335 3336</div> 3337<div class="button aem-GridColumn aem-GridColumn--default--12"> 3338<button type="button" id="modal-x" class="cmp-button" target="_self"> 3339 3340 <span class="cmp-button__icon cmp-button__icon--modal-x" aria-hidden="true"></span> 3341 3342 <!--Added context for the button text--> 3343</button> 3344</div> 3345<div class="container responsivegrid aem-GridColumn aem-GridColumn--default--12"> 3346 3347 3348 3349 3350 <div id="container-a01261b8c4" class="cmp-container"> 3351 3352 <div class="text vyv-spacing--top-sm-7 vyv-spacing--bottom-sm-7 vyvgarthcp-text--font-weight-sm"> 3353<div id="text-d934e9c581" class="cmp-text"> 3354 <p style=" text-align: left; 3355"><span class="vyv-now-approved-all-serotypes__pill">NOW APPROVED</span></p><h2 style=" text-align: left; 3356">for adults with gMG<br />across all serotypes<sup>1,2</sup>:</h2> 3357</div> 3358 3359 3360 3361</div> 3362<div class="text vyv-spacing--bottom-sm-7"> 3363<div id="text-9a56ed0bee" class="cmp-text"> 3364 <ul><li>AntiâAChR-Ab positive</li><li>AntiâMuSK-Ab positive</li><li>AntiâLRP4-Ab positive</li><li>Triple seronegative</li></ul> 3365</div> 3366 3367 3368 3369</div> 3370 3371 3372 </div> 3373 3374</div> 3375<div class="container responsivegrid flex flex-gap-xs _justify-center aem-GridColumn aem-GridColumn--default--12"> 3376 3377 3378 3379 3380 <div id="container-f90c61987b" class="cmp-container"> 3381 3382 <div class="button vyvh-cidp-button--primary"> 3383<a id="button-f41c505edd" class="cmp-button" href="#contact-a-rep" target="_self"> 3384 3385 3386 3387 <span class="cmp-button__text">Contact a rep</span> <!--Added context for the button text--> 3388</a> 3389</div> 3390<div class="text gmg-button"> 3391<div id="text-3373286987" class="cmp-text"> 3392 <div class="cmp-submenu-header--utility-item __with-sub"><span class="vyv-now-approved-all-serotypes__pi-trigger showInMobileMenu"><span class="cmp-button__text">Prescribing Information<span class="cmp-submenu-header--utility-item-chevron"></span></span></span><div class="cmp-submenu-header--sub--utility"><a href="https://www.argenx.com/product/vyvgart-hytrulo-prescribing-information.pdf" target="_blank" class="cmp-submenu-header--subItem" rel="noopener noreferrer">VYVGART Hytrulo</a><a href="https://www.argenx.com/product/vyvgart-prescribing-information.pdf" target="_blank" class="cmp-submenu-header--subItem" rel="noopener noreferrer">VYVGART</a></div></div> 3393</div> 3394 3395 3396 3397</div> 3398 3399 3400 </div> 3401 3402</div> 3403<div class="ghost aem-GridColumn aem-GridColumn--default--12"> 3404 3405</div> 3406<div class="ghost aem-GridColumn aem-GridColumn--default--12"> 3407 3408</div> 3409<div class="ghost aem-GridColumn aem-GridColumn--default--12"> 3410 3411</div> 3412<div class="text aem-GridColumn aem-GridColumn--default--12"> 3413<div id="text-1f27b42745" class="cmp-text"> 3414 <div class="vyv-now-approved-all-serotypes__footer-disclaimer"><p>Before prescribing VYVGART Hytrulo or VYVGART, please read the Important Safety Information below.</p><p>Triple seronegative=anti-AChR, anti-MuSK, and anti-LRP4 antibodies negative.<sup>1</sup><br />AChR-Ab=acetylcholine receptor antibody; gMG=generalized myasthenia gravis; LRP4-Ab=low-density lipoprotein receptor-related protein 4 antibody; MuSK-Ab=muscle-specific tyrosine kinase antibody.</p></div> 3415</div> 3416 3417 3418 3419</div> 3420 3421 3422</div> 3423 3424 </div> 3425 3426 3427</div> 3428 3429 3430</div> 3431 3432 </div> 3433 3434 3435</div> 3436 <!-- Video Section start --> 3437 3438 <!-- Video Section end --> 3439 3440 <!-- Content for the post video screen start --> 3441 3442 <!-- Content for the post video screen end --> 3443 </div> 3444 </div> 3445 </div> 3446 3447 3448 3449 3450</div> 3451 3452 3453 </div> 3454 3455</div> 3456 3457 3458 3459 3460
3461<script src="/etc.clientlibs/argenx/clientlibs/clientlib-argenx-global.lc-7e233df48ef69484095be8032747e9ad-lc.min.js"></script>
vendor: 1 bytes, line 3461
3461
3462<script src="/etc.clientlibs/argenx/clientlibs/clientlib-vyvgarthcp.lc-28595755efc817346321881572c9750c-lc.min.js"></script>
3462 3463 3464 3465 3466 3467 3468 3469
3470<script src="/etc.clientlibs/clientlibs/granite/jquery/granite/csrf.lc-652a558c3774088b61b0530c184710d1-lc.min.js"></script>
vendor: 1 bytes, line 3470
3470
3471<script src="/etc.clientlibs/core/wcm/components/commons/site/clientlibs/container.lc-0a6aff292f5cc42142779cde92054524-lc.min.js"></script>
vendor: 1 bytes, line 3471
3471
3472<script src="/etc.clientlibs/argenx/clientlibs/clientlib-base.lc-4b1c9a0268e3f6b9533f1026e0bb9c62-lc.min.js"></script>
3472 3473 3474 3475 3476 3477 3478 3479 3480 3481 3482 3483 3484 3485 3486 3487 3488
3488<script type="text/javascript">_satellite.pageBottom();</script>
3488 3489 3490 3491 3492 3493 3494 3495 3496 3497 3498</body> 3499</html>
Line numbers count LF bytes from the start of the resource, as the search results do. Vendor segments are library code the classifier recognised; they are stored but not indexed. Bytes are shown as Latin1 characters, one per byte.